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1 Introduction 
In recent years, the number of patients with end-stage renal disease has 
dramatically increased worldwide [1]. The progression of chronic renal disease 
represents one of the biggest challenges in nephrology. Regardless of whether the 
underlying disease is glomerulonephritis, tubulointerstitial disease, hypertensive or 
diabetic nephropathy, the histological picture of chronic renal disease is uniformly 
characterized by a progressive accumulation of extracellular matrix (ECM) proteins that 
obliterates renal function and leads to organ failure [2]. Enhanced understanding of the 
diverse pathogenetic mechanisms (vascular, metabolic, or immunologic disorders) has 
resulted in therapeutic advances. However, efforts to halt or even slow the progression 
of chronic renal disease have been largely unsuccessful. For this reason, there is still a 
great need for a better understanding of the molecular and cellular mechanisms 
involved in renal fibrosis.  
A number of previous studies have shown that the small molecule nitric oxide (NO) 
is critically involved in pathological matrix production and accumulation of the kidney. 
NO has been found to act as a protective signal molecule in blood pressure regulation, 
platelet deposition and cell infiltration and as a detrimental effector molecule and free 
radical in the immune response [3, 4, 5, 6, 7]. The enzyme soluble guanylate cyclase 
(sGC) represents the main signaling pathway of NO via generation of cyclic guanosine 
monophosphate (cGMP). So far, the role of sGC in renal disease has not been paid 
much attention to, since it has generally been assumed that this pathway is 
constitutively expressed and passes on the NO signal without any further modification 
of its own. The present study was designed to characterize the activity and expression 
of the NO-sGC-cGMP cascade in the injury, matrix expansion and progression phases 
of anti-thy1 antibody-induced renal disease of the rat. In addition, the novel 
pharmacological sGC stimulator Bay 41-2272 was used to enhance NO-sGC-cGMP 
signaling and to address the question of whether the beneficial and detrimental actions 
of NO in kidney disease can be therapeutically separated by this approach. 
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1.1 Pathogenesis and therapy of chronic progressive renal disease 
1.1.1 Histological and molecular characteristics 
The progression of end-stage renal disease is often owing to the progressive 
scarring and fibrosis of the kidney, with associated glomerulosclerosis, tubulointerstitial 
fibrosis and vascular sclerosis, resulting in the loss of filtration surface and renal 
function. As a fact of clinical relevance, the rate of decline of the renal function in 
patients with chronic renal disease correlates strongly with the extent of tubulointerstitial 
fibrosis [8]. Interactions among renal intrinsic cells, inflammatory cells and platelets lead 
to activation and proliferation of the cells to release inflammatory factors and also 
stimulate the accumulation of ECM, which is a hallmark of both acute and chronic renal 
disease [9]. With the expanding of our understanding of the pathogenesis of renal 
fibrosis, three mechanisms have been found to play an important role in the matrix 
expansion at molecular level [2, 10]: (1) an excessive synthesis of ECM components 
such as fibronectin, laminin, proteoglycans and collagens type I, type III and type IV; (2) 
an inhibited ECM degradation via increased inhibitors of proteinases, such as tissue 
inhibitors of matrix metalloproteinases (TIMPs) and plasminogen activator inhibitor type 
1 (PAI-1), and decreased matrix proteinases, such as matrix metalloproteinases 
(MMPs), collagenase (MMP-1), gelatinases (MMP-2/9), elastase and serin-protease; (3) 
increasing synthesis and expression on the cell membrane of a group of cell-matrix 
receptors called integrins, which interact with matrix components and infiltrative cells. 
1.1.2 The central role of TGF-beta in renal fibrosis 
Data from numerous studies of experimental and human diseases have shown that 
the persistent overexpression of the cytokine TGF-beta plays an important role in 
progressive renal disease from initial tissue injury to tissue fibrosis [10]. A number of 
factors known to be injurious to the kidney at the cellular level have now been shown to 
directly induce TGF-beta overexpression, including angiotensin II, mesangial cell 
stretch, fluid shear stress, high glucose levels, hypoxia, immune-complexes, protein 
trafficking, platelet derived growth factor and TGF-beta itself [11]. This increase of TGF-
beta directly leads to increased pathological matrix accumulation, independent of the 
initial injury, via the three molecular mechanisms introduced above: increased matrix 
production, decreased matrix degradation and increased integrin synthesis and 
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expression [2]. Thus the idea to normalize TGF-beta expression is a reasonable 
therapeutic target for renal fibrosis. Neutralizing the actions of TGF-beta with either an 
antibody or the proteoglycan decorin has been shown to prevent excessive matrix 
accumulation after tissue injury [12, 13]. In this study, TGF-beta expression is a very 
important parameter for evaluating the effectiveness of the new therapeutic method.  
1.1.3 The sequence of phases leading to progressive renal fibrosis 
Keeping in mind studies in dermal wounding, matrix accumulation in the kidney can 
be understood as renal wound healing. In this concept, various kinds of pathological 
stimuli such as hypertension, hyperglycemia or inflammation are uniformly perceived as 
injurious by the kidney (injury phase). Renal tissue injury, in turn, then leads to a 
uniform response with early cell proliferation and subsequent TGF-beta overexpression 
and matrix accumulation (matrix expansion phase). In acute renal disease, a single 
injurious stimulus leads to a transient TGF-beta overexpression and matrix 
accumulation that resolves by itself without over time intervention (normal wound 
healing). In contrast, in progressive chronic renal disease tissue injury is constant or 
repetitive, and subsequent TGF-beta overexpression becomes constant (pathological 
wound healing). As a result, the renal matrix expands continuously and impairs renal 
function progressively (progression phase).  
The concept of normal and pathological renal wound healing is exemplarily reflected 
in the rat model of anti-thy1-induced renal disease. While in animals with two kidneys, 
anti-thy1 antibody injection leads to acute and reversible ECM accumulation, injection 
of anti-thy1 antibody into uni-nephrectomized rats results in progressive renal fibrosis 
and insufficiency. The injury, matrix expansion and progression phases of this tandem 
model are characterized as follows: 
1. Injury phase. Injury in anti-thy1 renal disease is immunologically induced. 
Injection and binding of the antibody to the thy1 antigen on the mesangial cell 
surface, which is a glycosyl-phosphatidyl-inositol-anchored membrane protein 
[14], causes an acute complement-dependent and iNOS-mediated loss of 
mesangial cells (mesangiolysis) in the glomeruli [15]. This phase starts minutes 
after antibody injection and lasts approximately 24 hours. 
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2. Matrix expansion phase. Following mesangial cell injury, the matrix expansion 
phase is characterized by early mesangial cell proliferation and marked 
glomerular TGF-beta overexpression and ECM accumulation, which peaks at 7 
days after antibody injection [16]. 
3. Progression phase. Following the initial mesangial injury and matrix expansion, 
consistent with a decrease in TGF-beta production [2], the accumulation of ECM 
resolves by 6-8 weeks in animals with two kidneys. However, injection of 
monoclonal antibody into uni-nephrectomy animals demonstrates persistent 
proteinuria, marked TGF-beta expression and typical progressive fibrotic 
changes, first in the glomeruli, then in the tubulointerstitium. Over 16-20 weeks, 
the whole organ becomes fibrotic and the animals develop progressive renal 
insufficiency. This course is highly analogous to human chronic renal disease of 
glomerular origin. A continuous hyperfiltration injury of the remaining kidney may 
relate to the chronic progression.  
1.1.4 Therapeutic approaches to chronic progressive renal disease 
Progressive tissue fibrosis results from ongoing tissue “injury” and “matrix 
expansion”, so treatment of tissue fibrosis can aim at limiting tissue injury or at 
interfering directly with the molecular mechanisms mediating the matrix expansion, i.e. 
the overexpression of TGF-beta. Conventionally, therapies have aimed at reducing 
glomerular capillary pressure and the injuries that result, such as blood pressure and 
glycemic control in patients with hypertension and diabetes, but many patients still show 
progressive renal fibrosis with well controlled blood pressure and glycemia. Many 
studies have shown that angiotensin II blockade or low dietary protein have blood 
pressure-independent effects on the overexpression of TGF-beta and the ECM 
accumulation, besides reducing glomerular capillary pressure and thus decreasing 
tissue injury [10]. Future therapies should be focused on the mediators of renal fibrosis, 
such as TGF-beta overexpression, since the tissue “matrix expansion” and subsequent 
renal failure might be independent of the primary injury. Up until now, no therapies have 
been able to reduce TGF-beta expression to normal. New insights into second 
messengers and intracellular transduction pathways may suggest new interventions 
aimed at neutralizing fibrogenic mediators. 
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1.2 The L-arginine-NO pathway in renal disease 
The amino acid L-arginine is semi-essential and provides molecular substrate for the 
generation of NO, polyamines, L-proline and agmatine, all of which have been reported 
to be involved in renal pathology [3, 6, 17, 18]. Endogenous L-arginine synthesis occurs 
primarily in the proximal tubule of the kidney, using the non-protein amino acid L-
citrulline as a precursor [19]. Minor endogenous L-arginine synthesis has been 
observed in endothelial cells and macrophages [6, 18]. 
1.2.1 Two faces of the L-arginine-NO pathway 
L-arginine is the main endogenous source for the generation of NO by a highly 
regulated family of enzymes called NO synthase (NOS) that utilize O2 and NADPH as 
co-substrates and generate citrulline as a co-product [3, 6, 17]. NO is a diatomic and 
highly reactive radical gas and plays an important role in numerous biological 
processes ranging from neurotransmission to vasodilatation, and from inflammation to 
cell phenotype regulation. Once NO is produced, there exist two main pathways for it to 
interfere with renal physiology and pathophysiology: as an indirectly acting signaling 
and as a directly acting effector molecule [5]. At low physiological concentrations, NO 
acts locally as an important signaling molecule, because it diffuses freely across cell 
membranes with a diffusion coefficient 1.4 times that of oxygen in vivo, without being 
utilized by or reacting with intracellular molecules. The electronic structure of NO makes 
it an excellent ligand for heme-containing enzymes, which include cytochrome P450, 
NOS and sGC, allowing it to bind to the sGC heme at a low, non-toxic concentration 
[20]. Therefore, the signaling of NO is mainly mediated by the activation of sGC to 
increase cGMP levels and modify many of the biological effects of NO, including 
vasodilatation, inhibition of platelet activation and leukocyte migration [21]. 
At high concentrations, NO becomes a relatively non-specific destructive effector 
molecule of the immune system with a key role in mediating host defense, 
autoimmunity and self-destruction. Most of NO’s cytostatic and cytotoxic potential is 
induced via the irreversible reaction with superoxide radical (O2-) and formation of 
strong oxidant peroxynitrite (ONOO-) [22], which results in nitration of a tyrosine residue 
in proteins and subsequent damage, inhibition of key enzymes of the respiratory chain 
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and DNA synthesis by nitrolysation of their iron-containing catalytic elements and 
fragmentation of DNA. A high concentration of NO can result in autooxidation and the 
production of dinitrogen trioxide, which is injurious to biological tissues and causes 
chemical DNA alteration [23].  
1.2.2 NO synthases 
The glomerulus is a unique vascular network with three specialized cell types: 
endothelial cells, mesangial cells and visceral epithelial cells to express three potential 
nitric oxide synthase enzymes, endothelial, neuronal and inducible NOS (eNOS, nNOS 
and iNOS). Therefore, it has probably been more difficult to define roles for NO in 
glomerulonephritis than in most other immune and inflammatory diseases, despite a 
wealth of data [24]. It is assumed that different activities of NOS isoforms are essential 
for understanding the effects of in vivo NO. 
iNOS can be induced by inflammatory cytokines, especially LPS, interferon γ, 
interleukin-1, and TNF-alpha, elevated in macrophages, renal mesangial and tubular 
cells in the diseased kidney, and it produces high levels of NO in a calcium-independent 
manner [25]. In the presence of iNOS, NO is produced in high concentration and 
becomes an effector molecule, which plays a key role in the period of rapid initial 
response to immune injury in glomerulonephritis [24]. Its NO production depends on the 
extracellular L-arginine supply. 
eNOS and nNOS also called constitutive NOS (cNOS), are principally constitutively 
expressed and regulated by calcium [26]. Cell types containing cNOS generate low 
fluxes of NO for short periods of time, and signaling effects of NO are predominant. Its 
NO generation is not dependent on the extracellular L-arginine supply. eNOS is 
expressed by the endothelium. eNOS-dependent NO regulates vascular tone by 
promoting cGMP-dependent vascular smooth muscle cell relaxation, inhibits platelet 
aggregation and adhesion and prevents leukocyte adhesion [27]. nNOS also forms a 
class of cNOS and is localized in the macula densa and the efferent arterioles in the 
healthy human kidney [28]. nNOS is involved in the regulation of glomerular 
hemodynamics via tubulo-glomerular feedback and the release of renin [5]. 
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1.2.3 Effects of L-arginine supplementation on renal disease 
Over the last few years, L-arginine supplementation has been used as a novel 
therapy to modify the L-arginine-NO pathway and to slow the progression of renal 
fibrosis. However, the results of L-arginine treatment are controversial. Enhanced 
endothelial signaling NO production appears to mediate protective effects, while NO 
metabolized through the high-output iNOS seems to be a critical effector molecule in 
immune-mediated tissue damage [5]. In the injury phase of anti-thy1 glomerulonephritis, 
lupus nephritis, transplant rejection and acute tubular necrosis, where iNOS is 
increased, L-arginine intake results in the production of high concentrations of NO, 
which can worsen tissue injury and subsequent fibrosis. Yet in the matrix expansion 
phase of anti-thy1 glomerulonephritis, 5/6 nephrectomy, ureteral obstruction and 
nephropathy to diabetes and hypertension, L-arginine supplementation overcomes 
chronic NO deficiency by enhancing signaling molecule NO production via eNOS, which 
can reduce TGF-beta overexpression and matrix expansion. Additionally, there are 
several by-products in the pathway of L-arginine-NO, such as ornithine, polyamines and 
proline, which are essential for cellular proliferation and ECM deposits [5]. Interestingly, 
it has been found that L-arginine restriction limited TGF-beta and matrix accumulation, 
due to the limitation of substrate for polyamine and L-proline production [29]. These 
data suggest that both dietary L-arginine restriction and supplementation significantly 
limit matrix expansion, in contrast to normal L-arginine intake, which produces a more 
severe disease. The therapeutic and detrimental data of L-arginine supplementation 
reflect the two faces of the L-arginine-NO pathway. Investigating the question of how to 
enhance the signaling molecular effect and prevent the effector molecular effect is an 
aim of this study. 
1.3 NO-cGMP signaling in renal disease  
The most physiologically relevant action of NO mainly produced by eNOS is the 
activation of sGC and the conversion of GTP into the intracellular second messenger 
cGMP [30], a cyclic nucleotide, which regulates various cGMP effector systems such as 
protein kinases (PKG), phosphodiesterases (PDEs) and ion channels, to modify many 
physiological processes.  
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1.3.1 Distribution of NO-cGMP signaling in the glomeruli and the tubulointerstitium 
The NO-sGC-cGMP signaling pathway is spatially distributed in the glomerular and 
tubulointerstitial cells of the kidney to a great extent and explained in the following: 
§In the glomeruli 
As shown in Figure 1, eNOS distributes in endothelial cells of the glomerular 
vasculature, and nNOS is found primarily in the macula densa, both of which contribute 
to the production of NO signaling molecules in the glomeruli. Then NO diffuses freely to 
sGC, which expresses significantly in glomerular arteriolar walls and mesangial cells of 
the intra- and extraglomerular mesangium [31]. The activated sGC increases cGMP 
levels, which mediates its main downstream effects via PKG. PKG is a serine/threonine 
kinase including the soluble PKGI and the membrane-bound PKGII. PKGI is expressed 
in most tissues. In the glomeruli, PKGI is localized in arteriolar smooth muscle cells, 
including afferent and efferent arterioles and mesangial cells [32]. 
 
                                                                                                                         1 Introduction 
 - 9 - 
Figure 1: Distribution of NO-cGMP signaling in the glomeruli. L-Arginine (L-Arg), NO 
(Nitric oxide), Endothelial NO synthase (eNOS), Neuronal NOS (nNOS), cGMP (Cyclic 
guanosine monophosphate), GTP (Guanosine 5`-triphosphate), sGC (Soluble 
guanylate cyclase). 
§In the tubulointerstitium 
As shown in Figure 2, eNOS expresses in endothelial cells of the tubulointerstitial 
vasculature. Signaling molecule NO generated from eNOS activates sGC in cortical and 
medullary interstitial fibroblasts and along the renal vasculature outside the glomeruli to 
increase cGMP levels [31]. The cGMP stimulates PKGI, which has been found in 
microvascular pericytes and myofibroblasts [32]. 
 
Figure 2: Distribution of NO-cGMP signaling in the tubulointerstitium. L-Arginine (L-
Arg), NO (Nitric oxide), Endothelial NO synthase (eNOS), Neuronal NOS (nNOS), 
cGMP (Cyclic guanosine monophosphate), GTP (Guanosine 5`-triphosphate), sGC 
(Soluble guanylate cyclase). 
sGC has not been found in endothelial cells. A heterogeneous distribution of NOS 
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and sGC in the renal tissues suggests that NO acts through paracrine diffusion to its 
target for cGMP generation, rather than by intracellular signaling [31]. The anatomic 
features of these cells in renal tissue have also proved this, since in the kidney the 
endothelial cell is closely linked to the vasculature and the mesangium, and the macula 
densa is adjacent to the extraglomerular mesangium. This is supported by the 
coincident histochemical localization of PKG and sGC, implying that cGMP is a second 
messenger acting through intracellular signaling. 
1.3.2 The physiology of NO-cGMP signaling  
It was established by the mid-1970s that GC exists in membrane-bound and soluble 
forms in most cells [33]. In general, particulate GC does not respond to NO, since it has 
no heme prosthetic group in its structure. Purification of GC from the cytosolic 
compartment revealed the soluble isoform was a heterodimer composed of alpha- and 
beta-subunits and containing heme as a prosthetic group [34]. The most abundant 
subunits are alpha1 and beta1, which are found in many tissues [35]. NO binds to the 
enzyme’s prosthetic heme group that is linked to His-105 residue of the beta1-subunit 
induces conformational changes leading to an up to 400-fold increase in catalytic 
activity [36]. In vivo, sGC is activated at a low level of NO in the range of 5-100 nM; for 
NO >200 nM, nearly all of the binding sites for sGC are bound with NO [37]. Activated 
sGC catalyzes the conversion of GTP to cGMP and pyrophosphate [38].  
PKG, PDE and the ion channel are the three main downstream effectors of the NO-
cGMP pathway. PKGI can decrease cytosolic calcium and lead to smooth muscle 
relaxation [39]. Activation of PKG phosphorylates the thromboxane A2 receptor of 
platelet and then decreases platelets aggregation [40]. Furthermore, PKGI can 
phosphorylate vimentin, which is involved in neutrophil activation [41]. In contrast to 
PKGI, PKGII recently has been found in juxtaglomerular renin-secreting cells and in 
several nephron segments, contributing to renin release and ion transport in the tubule 
[42]. Therefore, the NO-cGMP pathway plays an important role in vasodilatation, 
inhibition of platelet aggregation and neutrophil infiltration. 
PDEs are enzymes which hydrolyze the 3´-phosphoester bond of cGMP to their 
biologically inactive noncyclic nucleotides 5´-GMP [43]. The cellular levels of cGMP are 
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defined by the balance between the activities of the synthesizing enzyme (sGC) and the 
catabolizing enzymes (PDEs). Investigations during recent years have revealed that 
PDEs are a critically important component of the NO-cGMP signal transduction. But the 
distribution of PDEs in the kidney is unclear. Studies of cultured rat mesangial cells 
show that atrial natriuretic peptide-induced cGMP accumulation is markedly decreased 
in the presence of angiotensin II, and this inhibition is abolished by IBMX [44]. Thus the 
PDE inhibitor might represent a novel class of pharmacologic agents suited for 
“signaling transduction pharmacotherapy” [45].  
The action of cation channels regulated by cellular cGMP levels is involved in the 
molecular basis of sensory systems of visualization and olfaction [32]. 
1.3.3 The pathophysiology of NO-cGMP signaling 
Only little is known about the regulation and expression of NO-cGMP signaling in 
renal fibrosis. Some data have shown that mechanisms behind the well known 
fibrogenic systems, such as the angiotensin system, the endothelin and the renal 
kallikrein-kinin system, are related to NO-cGMP signal transduction [46, 47, 48]. 
Angiotensin II inhibition could stimulate cGMP production and potentially contribute to 
renal protection in chronic nephritis [46]; and NO decreases secreted endothelin-1 due 
to the activation of sGC and increased cGMP generation [48]. In addition, nephrotoxic 
effects of cyclosporin A may result from the disruption of the bradykinin/sGC pathway 
[47]. It was shown that dexamethasone, one of several known selective inhibitors of 
iNOS, had a stimulatory effect on sGC in the glomeruli of rat kidney [49]. The contractile 
apparatus in the podocyte foot processes was proved to be a target of the cGMP 
signaling, which correlates with detachment of the cells from the glomerular basement 
membrane and is closely associated with many nephropathies [50]. Therefore, NO-
cGMP signal transduction might take part in the regulation of the kidney functions and 
the progression of kidney diseases. 
1.3.4 Pharmacological stimulators of sGC activity 
In this study, the transcriptional regulation of the NO-cGMP pathway was 
investigated and the pathway was modified to further define its role in progressive renal 
fibrosis. From the above information, we know that sGC is the most important receptor 
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for the ubiquitous biological messenger NO and is intimately involved in many signal 
transduction pathways. Activators of sGC are therefore very desirable as both 
pharmacological tools and potential therapeutics to probe the NO-cGMP pathway. In 
the 1990s, YC-1, chemically 3-(5’-hydroxymethyl-2’-furyl)-1-benzylindazole, was 
identified as a moderate and ~tenfold sGC activator. The actions of YC-1 are heme-
dependent, synergistic with NO and with the inhibition of PDE activity [51]. Recently, 
Stasch and colleagues reported on the discovery of a more potent sGC stimulator 
devoid of inhibiting PDE activity, Bay 41-2272, chemically 5-cyclopropyl-2-[1-(2-fluoro-
benzyl)-1Hpyrazolo(3,4-b)pyridin-3-yl]-pyrimidin-4-ylamine, which stimulates sGC up to 
30-fold in an NO-independent manner by interacting with cysteines 238 or 243 of the 
alpha1 subunit, which is different from the binding site of NO [52]. Although Bay 41-
2272 alone is not as strong a stimulator of sGC as NO, the specific activity of sGC 
could be 416-fold above the baseline through the combination of Bay 41-2272 and the 
NO donor [52]. These effects are probably mediated both by NO-independent 
stimulation of the enzyme and NO-dependent stimulation by sensitization of sGC 
towards endogenous NO. It has been demonstrated that, in a rat model of renin 
transgenic hypertension and spontaneously hypertensive rats (SHRs), oral 
administration of Bay 41-2272 lowered mean arterial pressure and showed antiplatelet 
activity, and enhanced survival in a low-NO rat model of hypertension [52]. In 
comparison to L-arginine, sGC stimulation with Bay 41-2272 avoids the potentially 
deleterious actions of the effector pathway of NO. A decrease in cGMP levels due to 
reduced sGC protein was found in the smooth muscle cells of SHRs, despite enhanced 
eNOS/NO production in the endothelium [53]. In this model, the sGC-cGMP pathway 
but not the eNOS/NO pathway was impaired, resulting in a decrease in cGMP 
production. So Bay 41-2272 was chosen to specifically enhance NO-cGMP signaling 
and further characterize the role of the sGC in renal pathological matrix accumulation. 
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1.4 Aim of the study 
We tested the hypothesis that the NO signal transduction via sGC plays its own, 
transcriptionally regulated role in pathological renal matrix expansion and that a 
selective enhancement of the sGC activity by Bay 41-2272 will limit kidney fibrosis in a 
pressure-independent manner. To test these hypotheses, the following protocols were 
carried out in the model of anti-thy1 glomerulonephritis. 
1. How is the glomerular NO-cGMP signal transduction regulated in the injury phase of 
acute anti-thy1 glomerulonephritis one day after antibody injection? How does this 
correlate with anti-thy1 antibody-induced inducible NO production and mesangial cell 
lysis? How will a pretreatment with Bay 41-2272 affect NO-induced glomerular injury? 
Bay 41-2272 treatment was started 6 days before disease induction. 
2. How is the glomerular NO-cGMP signal transduction altered in the matrix expansion 
phase of acute anti-thy1 glomerulonephritis seven days after antibody injection? How do 
the activity and expression of the NO-cGMP signaling pathway relate to glomerular 
TGF-beta overexpression and matrix accumulation? Will the administration of Bay 41-
2272 decrease glomerular matrix expansion? In this protocol, Bay 41-2272 treatment 
was started 24 hours after disease induction, so that the therapy began after the 
mesangial cell lysis had occurred. 
3. How is the tubulointerstitial and glomerular NO-cGMP signal transduction changed in 
the progression phase of chronic anti-thy1-induced glomerulosclerosis 16 weeks after 
antibody injection? Is the signal pathway concordantly or discordantly expressed at the 
glomerular and tubulointerstitial level? How do the activity and expression of the NO-
cGMP signaling pathway correlate with glomerulosclerosis, tubulointerstitial fibrosis and 
renal insufficiency? Will enhancement of sGC activity through Bay 41-2272 slow the 
progressive course of chronic anti-thy1-induced glomerulosclerosis? The actions of Bay 
41-2272 were compared side-by-side to the sole vasodilator hydralazine. In this protocol, 
treatment with Bay 41-2272 or hydralazine was started 1 week after disease induction. 
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2 Materials and methods 
2.1 Materials 
2.1.1 Chemicals, tools and instruments 
All materials used, chemicals and cell culture media, if not differently stated, were 
purchased from Sigma Chemical-Aldrich Co. (Taufkirchen, Germany). 
The following table lists the tools and instruments that were used during the 
experiments: 
Table 1: Tools and instruments used during the experiments. 
Blood pressure monitor Life Science Instruments, California, USA 
Camera Polaroid Polaroid GmbH, UK 
Cell culture container  NUNC™ Brand Products, Denmark 
Centrifuge 5417R Eppendorf-Netheler-Hinz GmbH, Hamburg, Germany 
Combitips plus, 0.5/2.5/5ml Eppendorf AG, Hamburg, Germany 
Cryo Tube™ Vials NUNC™ Brand Products, Denmark 
Electrophoresis Power Supply EPS 300 Pharmacia Biotech, Sweden 
Electrophoresis camber Hoefer Scientific Instruments, California, USA 
Embed machine Thermo electron corporation, Dreieich, Germany 
Eppendorf pipette/Multipette Eppendorf-Netheler-Hinz GmbH, Hamburg, Germany  
Eppendorf tips Eppendorf AG, Hamburg, Germany 
Eppendorf tubes 0.5/1.5/2.0ml Eppendorf AG, Hamburg, Germany 
Exam Gloves Kimberly-Clark, Roswell, USA 
Filter Unit Schleicher & Schuell GmbH, Dassel, Germany 
HiTrap Protein G HP Amersham Biosciences, Freiburg, Germany 
Homogenizer Labortechnik, Müllheim, Germany 
Incubator “HERA Cell” Heraeus Instruments, Hanau, Germany 
Laminal flow Heraeus Instruments, Hanau, Germany 
LightCycler Roche Diagnostic GmbH, Mannheim, Germany 
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LightCyclerTM-Kapillaren Boehringer Mannheim, Mannheim, Germany 
Megafuge 2.0R Heraeus Instruments, Hanau, Germany 
Metabolic cages 3701M081, Tecniplast, Buguggiate, Italian 
Metal sieves (ISO 3310-1 checked) Merck, Darmstadt, Germany 
Microplate Reader (MRX) DYNEX Technologies, Sullyfield Circle, USA 
Microscope Leica Microscopie & Systeme GmbH, Wetzlar, Germany 
Microscope Slides, Super Frost Plus R. Langenbrinck, Emmendingen, Germany 
Microscope Cover Glasses Gerhard Menzel GmbH, Braunschweig, Germany 
Microtiter plate shaker TITRAMAX 101 Heidolph Instruments, Schwabach, Germany 
Microtome Microm International GmbH, Walldorf, Germany 
Minishaker MS1 IKA Works Inc. Wilmington, Germany 
NONC-Immuno 96-Well shape plates NUNC A/S, Roskilde, Denmark 
Operation instruments: forceps, etc. Medicalis Medizintechnologie, Garbsen, Germany 
Parafilm American National Can™, Greenwich, USA 
Pipette 2, 5, and 25 ml  Greiner Bio-one GmbH, Frickenhausen, Germany 
Microwave  Bosch, Germany 
Multi-adapter for S-Monovette Sarstedt, Nümbrecht, Germany 
pH Meter Wissenschaftlich Technische Werkstätten, Weilheim, Germany 
Polypropylene Conical Tube, 15/50ml Becton Dickinson, Franklin Lakes, USA 
RNA/DNA-Calculator „Gene Quant “ Pharmacia Biotech. Sweden 
S-Monovette 9ml with EDTA Sarstedt, Nümbrecht, Germany 
Scale Sartorius, Göttingen, Germany 
Shaker, “Big squid” IKA-WERKE GmbH, Staufen, Germany 
Single-use fine dosage syringe B.Braun Melsungen AG, Melsungen, Germany 
Sterile Syringe 1ml Becton Dickinson GmbH, Heidelberg, Germany 
Thermomixer Compact Eppendorf AG, Hamburg, Germany 
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Tissue culture Plates/Dishes Becton Dickinson, Franklin Lakes, USA 
TRIO-Thermoblock Biotron GmbH, Germany 
UV-20 light Hoefer Pharmacia Biotech INC, San Francisco, USA 
Vortex-2-Genie Scientific Industries (SI), Bohemia, N.Y.USA 
2.1.2 Computer and software 
1. Measurements of ELISA and data analysis were carried out using BioLinx™ 
(Dynatech Laboratories, Inc, Sullyfield Circle, USA). 
2. For the analysis of the Real time-PCR, LightCycler 3.5.3 (LightCycler-Software, 
Roche, Mannheim, Germany) was used. 
3. Statistical analysis was done using SPSS 11.0 (SPSS Inc. Chicago, USA) and 
Excel 2000 (Microsoft Corporation, USA). 
4. Graphical representations were done using Excel 2000 and Sigma PlotTM (Systat 
Software GmbH, Scientific Graphic Software 7.0, Erkrath, Germany). 
5. The final thesis was written using Word 2000 (under Windows NT, Microsoft 
Corporation, USA) and Reference Manager (Adept Scientific GmbH, Frankfurt, 
Germany). 
2.2 Animal experiments 
Animal care and experiments were in conformity with the guidelines of the American 
Physiological Society and were approved by local authorities (animal experiments 
register No. G 0240/02, Landesamt für Arbeitsschutz, Gesundheitsschutz und 
technische Sicherheit Berlin). 
2.2.1 Animals 
Male Wistar rats (initial weight of 180-250 g, Charles River, Sulzfeld, Germany) were 
used in this study. Animals were housed in the center of the animal laboratory 
(Tucholsky-Straße 2, 10117 Berlin, Germany), caged in pairs with free access to food 
and drinking water in a constant temperature room with a 12-hour dark/12-hour light 
cycle. The animals were visited daily, and the consumption of food and drinking water 
and body weight were monitored.  
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2.2.2 Production of monoclonal antibody OX-7 and mAb 1-22-3 
2.2.2.1 Cell culture 
Monoclonal mouse hybrid granny cells of the OX-7 (company center of Applied 
Microbiology & Research, Salisbury, UK) and mAb 1-22-3 (Gift from Fuijo Shimizu, 
Nephrology, Niigata University Graduate School of Medical and Dental Sciences, 
Niigata, Japan) were used. The cells stored at -70°C were transferred under sterile 
conditions into the following culture medium (Biochrom AG, Berlin, Germany): RPMI 
1640 supplemented with 9% fetal calf serum, 1.6% G-50 glucose solution, 0.3% 
HEPES, 100 U/ml Penicillin and 100 µg/ml Streptomycin in a culture bottle, incubated at 
37°C/5% CO2 and passaged at confluence. The cells were microscopically controlled 
every 48 hours by means of Tryptan Blue staining, which differentiates vital and non-
vital cells. At the same time, the pH of the culture medium was determined. Every two 
days, the cell culture medium was changed and the cells proliferated. 35 ml cell 
suspension with 0.5x106 /ml cells were transferred into a miniPERM cell culture module 
(Heraeus Instruments, Hanau, Germany) and put on a lathe fixture (Heraeus 
Instruments, Hanau, Germany) for being mixed to achieve a better oxygen supply to the 
cells. When the cells in the culture module reached a density of 8x106 /ml, the contents 
of the culture modules were divided into 4 miniPERM culture modules. After incubation 
for 24 and/or 48 hours, the medium was changed according to cell growth and the pH of 
medium. If cell density reached 11.5 x106 /ml, 17 ml were taken out of the culture 
module and stored at 4°C for later purification. The cell culture module was filled up with 
culture medium again to a total volume of 35 ml.  
2.2.2.2 Purification of the monoclonal antibody OX-7/mAb 1-22-3 
To purify the IgG fraction, the cell culture suspension was mixed with binding buffer 
(20 mM sodium phosphate, pH 7.0). The mixture was filled to a pre-equilibrated Protein 
G column at a flow velocity of 0.5 ml/min. There is a strong affinity between IgG and 
protein G at pH 7. Then the IgG was eluted with elution buffer (0.1 mol/l glycine-HCl, pH 
2.7) and neutralized with 1 mol/l Tris-HCl (pH 9). After extensive dialysis against PBS 
(Biochrom AG, Berlin, Germany) (pH 7.4) for 24 hours, the antibody concentration was 
adjusted to 1 mg/ml by reading the absorbance at 280 nm and stored at -70°C until use.  
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2.2.3 Models of anti-thy1-induced renal disease 
2.2.3.1 Acute anti-thy1 glomerulonephritis  
The acute anti-thy1 glomerulonephritis (aGN) model was induced by tail vein 
injection of monoclonal antibody OX-7 (1 mg/kg body weight in PBS) under light ether 
(Chinosolfabrik, Seelze, Germany) anesthesia. Control animals were injected with equal 
volumes of PBS. 
2.2.3.2 Chronic anti-thy1-induced glomerulosclerosis 
In the anti-thy1-induced chronic glomerulosclerosis (cGS) model, before antibody 
injection, unilateral nephrectomy was performed under anesthesia of 0.1 mg ketanest/ 
0.01 mg xylazin per 100 g body weight (ketamin 10%, WDT, Garbsen, Germany; 
Rompun 2%, Bayer Vital GmbH, Leverkusen, Germany). A small flank incision was 
made, then the right kidney was separated and removed after the right renal artery, vein 
and ureter were ligated at the renal pedicle. The monoclonal antibody mAb 1-22-3 was 
injected at a high dose of 5 mg/kg body weight in PBS three days after uni-nephrectomy. 
Control animals with and without uni-nephrectomy were injected with equal volumes of 
PBS. 
2.2.4 Food and drinking water intakes 
All animals were fed a normal protein diet (Altromin No.1311, Altromin, Lage, 
Germany) for at least three days before the start of the experiment to allow equilibration. 
Dependent on body weight, the drugs were added to the food or the drinking water of 
treated animals. The calculated amount of the drugs was added to 1 kg flour of the 
standard rat food stated as above and mixed evenly. Then 600 ml water were added to 
the mixture and mixed, until a homogeneous dough developed. The dough was strongly 
rolled out about 1 cm thick and shaped by means of biscuit mold. The biscuits were 
dried with the help of a warm air fan. The average food and water consumptions of the 
animals from preliminary tests were about 25 g/day and 50 ml/day. The active 
substance quantity given is based on this consumption. In order to ensure that the 
calculated active substance quantity was actually ingested, the food and water 
consumptions of the treated group were controlled daily. 
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Table 2: Contents of the food (average content in 1 kg diet). 
Contents of breeding diet  
Raw protein 22.50% 
Lysine 1.20% 
Raw fat 5% 
Raw fiber 4.50% 
Raw ash 6.50% 
Calcium 0.90% 
Phosphorus 0.70% 
Vitamin A 15000 IE 
Vitamin D3 600 IE 
Vitamin E 75 mg 
Copper 5 mg 
2.2.5 Drug administration 
Bay 41-2272 (10 mg/kg body weight/day) was added to the food meal. This dose 
has previously been reported to reduce sufficiently the blood pressure in spontaneously 
hypertensive rats [52]. Bay 41-2272 was generously provided by Dr. Johannes-Peter 
Stasch, Pharma Research Center, Bayer AG, Wuppertal, Germany.  
Hydralazine was given with the drinking water in a dose of 15 mg/kg body 
weight/day. The dosage was adjusted according to the blood pressure, which in the 
hydralazine-treated rats should be the same as that of Bay 41-2272-treated rats. 
Although the precise mechanism of action of hydralazine is not fully understood, it 
apparently lowers blood pressure by exerting a peripheral vasodilating effect through a 
direct relaxation of vascular smooth muscles, which might result from the inhibition of 
the release of Ca2+ from the sarcoplasmic reticulum [54].  
2.3 Experimental design 
The NO-cGMP signaling cascade was separately analyzed in the injury phase of 
acute anti-thy1 glomerulonephritis (protocol 1), the matrix expansion phase of acute 
anti-thy1 glomerulonephritis (protocol 2) and the anti-thy1-induced chronic 
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glomerulosclerosis (protocol 3). The expression analysis of the NO-cGMP cascade 
included mRNA expression of eNOS and alpha1 and beta1 sGC. The activity of sGC 
was determined at basal level and in response to a defined amount of NO in freshly 
isolated glomeruli and cortical tissues ex vivo. 
2.3.1 Protocol 1: NO-cGMP signal transduction in the injury phase of acute anti-thy1 
glomerulonephritis (day 1 after antibody injection) 
Six days before antibody injection, male Wistar rats were divided into the following 
groups: 
A) PBS-injected controls (Control, n=6);  
B) anti-thy1 antibody-injected animals, no treatment (aGN, n=10);  
C) anti-thy1 antibody-injected animals plus Bay 41-2272 (aGN+Bay 41-2272, 
n=10). 
Treatment with Bay 41-2272 was started 6 days before and continued until 24 hours 
after OX-7 injection. On the fifth day, systolic blood pressure was measured. On the 
sixth day, glomerulonephritis was induced and 24-hour urine specimens were collected. 
The animals were sacrificed 24 hours after disease induction, when mesangial cell lysis 
develops and inducible glomerular NO production is markedly elevated [55]. In the 
injury protocol, urinary protein, glomerular cell number, NO production and iNOS mRNA 
expression were analyzed as indicators of mesangial cell injury. 
2.3.2 Protocol 2: NO-cGMP signal transduction in the matrix expansion phase of acute 
anti-thy1 glomerulonephritis (day 7 after antibody injection) 
One day after antibody injection, male Wistar rats were assigned to the following 
groups:  
A) PBS-injected controls (Control, n=6);  
B) anti-thy1 antibody-injected animals, no treatment (aGN, n=10);  
C) anti-thy1 antibody-injected animals plus Bay 41-2272 (aGN+Bay 41-2272, 
n=12). 
Bay 41-2272 treatment was started 24 hours after anti-thy1 antibody injection for 6 
days, when mesangial cell lysis is complete and the fibrotic response begins [56]. On 
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the fifth day, systolic blood pressure was measured. On the sixth day, 24-hour urine 
specimens were collected. The animals were sacrificed seven days after disease 
induction, when the fibrotic response peaks [16]. In this protocol, urinary protein and 
parameters of glomerular matrix expansion, including glomerular matrix score and 
expression of TGF-beta1, fibronectin and PAI-1, were measured. In addition, mRNA 
expression of P-selectin and immunohistological detection of glomerular macrophage 
infiltration and fibrinogen deposition were also analyzed. 
2.3.3 Protocol 3: NO-cGMP signal transduction in anti-thy1-induced chronic 
glomerulosclerosis (progression phase) 
A 24-hour proteinuria was measured one week after anti-thy1 antibody injection. On 
the basis of the actual 24-hour proteinuria achieved, the diseased animals were 
randomized and assigned to the following groups:  
A) non-nephrectomized, PBS-injected controls (2-K Control, n=5);  
B) uni-nephrectomized, PBS-injected controls (1-K Control, n=4);  
C) uni-nephrectomized, anti-thy1-injected animals, no treatment (cGS, n=18);  
D) uni-nephrectomized, anti-thy1-injected animals treated with Bay 41-2272 
(cGS+Bay 41-2272, n=18);  
E) uni-nephrectomized, anti-thy1-injected animals treated with hydralazine 
(cGS+Hydralazine, n=12).  
To avoid interference with the induction of the disease, Bay 41-2272 and 
hydralazine treatments were started one week after antibody injection. Systolic blood 
pressure was assessed in week 8 and the days before sacrifice. 24-hour proteinuria 
was measured after 1, 4, 8, 12 and 16 weeks. The animals were sacrificed 16 weeks 
after disease induction. Proteinuria, blood pressure, tissue fibrosis, macrophage 
infiltration and kidney function were determined. Glomerular and tubulointerstitial 
changes were analyzed separately. Glomeruli were isolated by a graded sieving 
technique. Since renal cortex consists mainly of tubulointerstitial tissue (>95%), it was 
used as representative of the tubulointerstitium. Analysis of fibrosis involved a 
histological scoring of the matrix accumulation and molecular analysis of the expression 
of the key fibrosis marker and mediator TGF-beta1, the matrix protein fibronectin and 
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the matrix degradation inhibitor PAI-1. Tubulointerstitial and glomerular macrophage 
infiltrations were analyzed by immunohistochemistry using an ED1-antibody. In addition, 
mRNA expression of the adhesion molecule P-selectin was measured. Blood creatinine 
and urea concentrations, calculated creatinine clearance and blood hematocrit served 
as markers of renal function. 
2.4 Harvesting of materials 
2.4.1 Urine collection 
For urine collection, the animals were individually housed in metabolic cages for 24 
hours. The metabolic cages are equipped with a special funnel and cone design that 
effectively separates urine from feces, food remainder and water. To avoid excessive 
bacterial growth and an associated change of some examined parameters, 100 µl 
penicillin/Streptomycin (10000 U/10000 µg/ml) were pipetted into the urine collection 
tube. During their accommodation in metabolic cages, the animals had free access to 
food and drinking water. After 24 hours, urine was collected, centrifuged for 10 min at 
10000 rpm to remove particulate matter and frozen for later measurements at -25°C.  
2.4.2 Removal of kidney and blood and further processing 
2.4.2.1 Removal of kidney and blood 
At the end of the experiment, the rats were anaesthetized with ketamine and 
Xylazine and sacrificed. The animals were fixed in an upside-down position. Then the 
abdominal cavity was opened with a u-shaped cut from penis to both rib elbows 
endings. Blood was drawn from the lower abdominal aorta until the heartbeat stopped. 
Ice-cold sterile PBS was then injected, until the heart beat again. Under the liver, the 
large body artery and the lower vein were clamped and then the lower vein was cut. 
The kidney was perfused with 40 ml ice-cold sterile PBS under stable pressure. The 
blood-empty kidneys were then removed and stored in 50 ml ice-cold sterile PBS until 
further processing. The blood was filled into EDTA-coated tubes, centrifuged at 3000 
rpm and 4°C for 10 min, aliquot according to measured parameters, e.g. urea, 
creatinine and cGMP [20 µl 5 mM IBMX (Alexis GmbH, Grünberg, Germany) was 
added to 980 µl of plasma to block cGMP degeneration], and they were frozen at -25°C. 
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2.4.2.2 Isolation of glomeruli 
The kidneys were separated from fats and capsules. A fifth of the total kidney was 
separated at a kidney pole. Different parts of the kidney pole were divided for fixing in 
10% neutral buffered formalin (Merk, Darmstadt, Germany) and shock-frozen by liquid 
nitrogen for RNA investigation and then kept at -80°C. Then the remaining kidney tissue 
was halved and the renal pelvis was cut out with small curved shears. The kidney tissue 
was chopped up with a blade on an ice-cold glass until a homogeneous viscous mass 
developed, which was then passed through metal sieves and mechanically broken 
down to yield glomeruli. The tissue mass was transferred to the highest sieve with the 
mesh size of 160 µm, pressed by means of glass spatulas and washed with PBS. 
Tissues accumulated on the second sieve with the mesh size of 125 µm. The tissues 
were collected and flushed directly and vigorously with PBS several times. The 
glomeruli accumulated on the lowest sieve with the mesh size of 71 µm and were 
collected by means of indirect 300 ml PBS washing. The isolated glomeruli were then 
transferred into a 50 ml PBS tube and centrifuged for 5 min at 1900 rpm and 4°C. 
2.4.2.3 Preparation of tubulointerstitial tissue 
Since renal cortex consists mainly of tubulointerstitial tissue (>95%), it was used as 
representative of the tubulointerstitium. The kidney cortex was chopped up with a blade 
on an ice-cold glass, and then 60 mg chopped cortex were taken into 6 ml culture 
medium at a density of 10 mg/ml for the cortical cell culture. 
2.4.3 Cell culture 
In protocol 1 (injury phase), basal and LPS-stimulated nitrite production of glomeruli 
was measured in glomerular culture with or without LPS. In protocol 2 (matrix 
expansion phase), glomerular TGF-beta1, fibronectin and PAI-1 production and basal 
and NO-stimulated sGC activity were measured in glomerular culture with or without 
DEA/NO; in addition, glomerular TGF-beta1 production in vitro in the presence of Bay 
41-2272 was also analyzed. In protocol 3 (progression phase), TGF-beta1, fibronectin 
and PAI-1 production and basal and NO-stimulated sGC activity were measured in 
glomerular and tubulointerstitial culture with or without DEA/NO. Two or three samples 
from each animal were analyzed. 
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The culture medium was made from DMEM supplemented with 0.1 U/ml insulin, 100 
U/ml penicillin and 100 µg/ml streptomycin (Biochrom AG, Berlin, Germany). Cortical 
cell cultures were set as described above. The isolated and centrifuged glomeruli were 
resuspended in 5 ml culture medium. 10 µl were taken and extended on a Petri dish in 
the form of a line. Then glomeruli were microscopically counted and the concentration 
of glomeruli was adjusted to 2000 per ml. Glomerular concentrations were determined 
to achieve the comparability of different samples. After 48 hours of incubation at 
37°C/5% CO2, supernatants were harvested and stored at -25°C until analysis of TGF-
beta1, fibronectin or PAI-1 contents.  
In order to prove the direct regulation of TGF-beta1 production by stimulated sGC 
independent of blood pressure, glomeruli from 6 normal and 8 nephritic rats (protocol 2) 
were resuspended in DMEM culture medium at a density of 2000 per ml. The sGC 
stimulator Bay 41-2272 was added in increasing concentrations: 0, 0.1, 1, 5 and 10 µM. 
After 48 hours of incubation at 37°C/5% CO2, supernatants were harvested and stored 
at -25°C until analysis of glomerular TGF-beta1 production. 
In protocol 1 (injury), glomeruli were cultured at a density of 2000 per ml for 48 
hours (basal NO glomerular production). Additional samples were cultured in the 
presence of 10 µg LPS from Escherichia. Coli (serotype 0127:B8) to stimulate inducible 
NO production (stimulated glomerular NO production). Nitrite served as indicator of NO 
production and was determined by the Griess reaction in glomerular culture 
supernatants. 
150 µl cortical cells and glomeruli in DMEM were pipetted into a 96-well microplate 
for further cGMP assessment. The microplate with samples was first prewarmed at 
37°C/5% CO2 for one hour, then was added 20 µl 5 mM IBMX and incubated for 10 min 
to inhibit cGMP degradation. NO-mediated stimulation was studied by addition of 20 µl 
1 mM DEA/NO (Alexis GmbH, Grünberg, Germany). After 10 min of incubation, the 
microplate was put on ice to stop the reaction and added 20 µl 5% 
dodecytrimethylammonium bromide to facilitate cell lysis. A microscopic evaluation with 
Trypan blue was carried out to check whether the cells were lysed. Lysed cells were 
stored at -80°C for cGMP ELISA. 
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The remaining glomeruli were homogenized in Trizol™ Reagent (Invitrogen life 
technologies, Carlsbad CA, USA). After 5 min of incubation at room temperature, the 
samples were stored at -80°C until RNA isolation.  
2.5 Measurements 
2.5.1 Systolic blood pressure  
Systolic blood pressure was measured in trained conscious animals by a tail cuff 
method with plethysmography [57]. The animals were fixed in a dark acrylic glass pipe. 
This pipe was kept at a moderate temperature in an ambient chamber. After 5 min 
acclimatization, a seal with an integrated sensor was put around the rats’ tails about 1 
cm before the tail root, and in each case three measurements were made, whose 
values were averaged. Before the actual beginning of the experiment, the animals were 
accustomed to the procedure, in order to avoid misleadingly high values caused by 
stress. 
2.5.2 Renal function 
Plasma creatinine and urea levels and creatinine clearance were determined as 
markers of the excretory kidney function and blood hematocrit was analyzed as the 
renal endocrine, erythropoietin-producing capacity. Plasma and urine creatinine and 
plasma urea were determined with the analyzer Hitachi 747-400 (Diamond Diagnostic 
Inc., Holliston, USA). For the determination, the method of Jaffé is used in this 
equipment, in which creatinine in alkaline solution and picrate form a yellow-orange 
colored complex which can be photometrically measured. The color of the complex 
relates directly to the concentration of creatinine. The creatinine clearance was 
calculated on the basis of: (Urinary creatinine x urine volume)/ (serum creatinine x 
collecting time 1440 min). Urea is measured with a kinetic UV test. At first urea reacts 
with water and is converted by urease into ammonium and carbon dioxide. Then the 
produced ammonium reacts with α-Ketoglutarat and NADH (nicotine amide adenine 
dinucleotid hydrogen). The conversion of NADH is afterwards kinetically measured. 
Hematocrit was determined by the percentage of blood cells in blood plasma after a 10 
min/ 3000 rpm centrifugation. 
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2.5.3 Rat tail bleeding time  
Shortly before the anesthetized rats were sacrificed, the dorsal part of the tail was 
cut with a standardized incision (10 mm long, 1 mm deep) with a sterile razor blade. 
The bleeding time was then measured [58]. 
2.5.4 Urinary protein  
The total urinary protein was determined by the Pyrogallol red method in a color 
metric terminator point with the Pyrogallol-Red method kit (Biocon Diagnostik, 
Marienhagen, Germany). The Pyrogallol-red-molybdate complex used is bound to 
proteins. The binding causes a shift of the absorbance peak to 600 nm. The color 
intensity can directly reflect the total protein concentration [59]. Due to the presence of 
detergents in the reagents, different types of proteins give similar recoveries [60]. The 
sample concentration could be read by a standard curve consisting of six dilutions with 
protein concentrations from 0 to 5 g/l. 10 µl standard and/or sample were added to a 
96-well microplate. Then 350 µl ready for use reagent were pipetted into each well. 
Standard dilutions, samples and empty value were measured in duplicate. After 10 min 
response time, the developed color product could be read photometrically with a 
wavelength of 570 nm on the plate reader. The protein concentrations of samples were 
calculated: A (absorbance) sample/A standard x urine volume x dilution=proteins in 
mg/day. 
2.5.5 Basal and LPS-stimulated nitrite production 
Nitrites are stable oxidative end products of NO and served as indicators of 
endogenous NO synthesis [3]. Nitrite levels in cell culture supernatants were measured 
by the Griess reaction [61]. 10 standard samples (50, 25, 20, 15, 10, 7.5, 5, 2.5, 1, 0 µM) 
were prepared with sodium nitrite. 50 µl of sample were then mixed with 100 µl Griess 
reagent [0.05% N-(1-naphthyl) ethylene diamine dihydrochloride, 0.5% sulfanilamide in 
45% glacial acetic acid] in 96-well plates. After 10-min incubation in the dark, 
absorbance was read at 570 nm in an automated plate reader. Then basal and LPS-
stimulated glomerular NO production were analyzed. 
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2.5.6 Histology 
Kidney tissue was fixed with 10% neutral buffered formalin for 12 hours and then 
embedded in paraffin. The tissue was transferred to an embed automat after initial 
drainage in paraffin. The paraffin-impregnated tissue was poured in block and cut 2-3 
µm thick with the microtome after hardening. All slides were dried afterwards for 24 
hours at 37°C in the reheating furnace. The slides were deparaffinized before the stain 
procedure.  
Uncoated slides were used for PAS staining. The slides were brought into xylene 
(J.T.Baker, Deventer, Holland) twice for 10 min and transferred afterwards for 2 min into 
the descending alcohol row (Herbeta-Arzneimittel, Berlin, Germany) (ethanol 100%, 
100%, 96%, 96%, 80%, 50%, and distilled water).  
For the immunohistological staining, the slides were transferred into fresh xylene 
twice for 10 min and into each unit of the descending alcohol row for 10 min. 
Subsequently, the deparaffinized slides were cooked in a pot with citrate buffer by pH 
6.5 at 96°C for 10 min and kept in distilled water after cooling until the subsequent 
procedure. For the immunohistology, the slides remained in distilled water before the 
embedment with ImmuMount (Thermo Shandon, USA). 
2.5.6.1 PAS staining 
For this staining, the following solutions were first set:  
A) Alcoholic periodic acid solution: 1 g periodic acid was dissolved in 30 ml 
distilled water. Then 70 ml 100% ethanol were mixed in the solution.  
B) Alcoholic disulphide solution: 0.5 g potassium disulphide were dissolved in 
30 ml distilled water, and then 70 ml 100% ethanol were added.  
C) Schiff reagent commercial mixture (Merk, Darmstadt, Germany). 
After deparaffinization, the slides were placed in 1% periodic acid for 10 min. Then 
they were washed in running tap water for 5 min and afterwards briefly in disulphide 
solution. The slides were then brought into the Schiff reagent warmed to 40°C and 
incubated at 40°C for 20 min. Then the slides were dipped briefly in disulphide solution 
again and washed in running tap water for 10 min. After 5 min’s counterstain in Meyer’s 
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hematoxylin (Merk, Darmstadt, Germany), the slides were blued for 10 min in running 
tap water. Then the slides were transferred into the ascending alcohol row for 1 min (in 
distilled water, and ethanol 50%, 80%, 96%, 96%, 100%, 100%, and twice xylene) and 
covered up with Corbit-Balsam (R.Langenbrink, Emmendingen, Germany) (37°C). Stain 
result: Connective tissue: blue, Cytoplasm: pink, Nucleus: blue-black and Acidic 
Mucopolysaccharide: bright magenta.  
2.5.6.2 ED1 staining 
Before the staining, tris-buffered saline (TBS) had to be manufactured. At first two 
master solutions were set. Master solution A: 0.5 mol/l Tris-solution, consisting of 60.55 
g Tris (hydroxymethyl)-aminomethan /1 l distilled water. Master solution B: 1.5 mol/l 
NaCl solution, consisting of 87.66 g NaCl/1 l distilled water. The master solutions were 
kept at 4°C. TBS was set before use in the ratio of 1 part solution A +1 part solution B 
+8 parts distilled water, and then adjusted to pH 7.6 with 0.5 mol/l HCl. 
The immunohistological staining of ED1 was accomplished with the paraffin slides in 
a humidified chamber. The slides were first deparaffinized and brought into the 
descending alcohol row and cooked in citrate buffer as described above. Then the 
sections on the slides were circled with a tallow pencil (DAKO Cytomation, Hamburg, 
Germany) and placed in TBS buffers. Then the sections were blocked with inactivated 
fetal calf serum for 30 min. The sections were incubated with the primary antibody 
Mouse anti-Rat ED1 (Serotec GmbH, Düsseldorf, Germany) for 30 min. The antibody 
was diluted 1:100 with an antibody dilution medium (1 part inactivated fetal calf serum, 
1 part RPMI medium, 8 parts distilled water). There were three cuts on each slide. One 
cut served as negative control and was incubated only with antibody dilution medium 
instead of the primary antibody. They were rinsed with TBS buffer after the incubation. 
Then incubation with the secondary antibody Rabbit anti-Mouse-Ig (DAKO) followed for 
30 min. After 30 min incubation with APAAP Mouse-Ig (DAKO), the sections were 
rinsed again with TBS buffer and incubated with the substrate fast red (DAKO) about 5 
min. The color was microscopically controlled. Then the sections were rinsed with 
distilled water and placed in Mayer’s Hematoxylin as counterstaining for 1min. Then 
they were washed with running tap water for 10 min and covered up with ImmuMount. 
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Stain result: cell nucleus: blue-black, immunocomplexes: bright red. 
2.5.6.3 Fibrinogen staining 
The immunohistological staining of fibrinogen was accomplished with the paraffin 
slides in a humidified chamber. The slides were first deparaffinized and brought into the 
descending alcohol row and cooked in citrate buffer as described above. Then the 
sections on the slides were circled with a tallow pencil and placed in TBS buffers. Then 
the sections were blocked with 3% bovine albumin for 30 min. The sections were 
incubated with the primary antibody Rabbit anti-Human fibrinogen (DAKO Cytomation, 
Hamburg, Germany) for 30 min. The antibody was diluted 1:200 with an antibody 
diluent. There were three cuts on each slide. One cut served as negative control and 
was incubated only with antibody diluent instead of the primary antibody. They were 
rinsed with TBS buffer after the incubation. Then incubation with the secondary 
antibody Mouse anti-Rabbit-Ig (DAKO) followed for 30 min. And then incubation with 
the third antibody Rabbit anti-Mouse-Ig was executed for 30 min after TBS rinsing. After 
30 min incubation with APAAP Mouse-Ig, the sections were rinsed again with TBS and 
incubated with the substrate fast red about 5 min. The color was microscopically 
controlled. Then the sections were rinsed with distilled water again and placed in 
Mayer’s Hematoxylin as counterstaining for 1 min. Then they were washed with running 
tap water for 10 min and covered up with ImmuMount. Stain result: cell nucleus: blue-
black, immunocomplexes: bright red. 
2.5.6.4 Histological evaluation 
All microscopic examinations were performed in a blinded fashion. Three µm 
sections of paraffin-embedded tissue were stained with PAS. In protocol 1, the number 
of cell nuclei was counted in 15 glomeruli of 80-100µm diameter from each animal for 
calculation of mesangial cell lysis [55]. In protocol 2, the histological evaluation was 
made by means of light microscopy according to the semiquantitative procedure [56]. 
The percentage of mesangial matrix-occupying area in 20 glomeruli from each rat was 
graded as: 0=0%, 1=0-25%, 2=26-50%, 3=51-75% and 4=76-100%. In protocol 3, 
glomerular matrix expansion was evaluated by rating the mesangial matrix-occupying 
area in 15 glomeruli from each rat, using the same scoring system as above. 
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Tubulointerstitial matrix deposition was determined in 15 randomly selected cortical 
areas per sample observed at x200 magnification, using the following scale: 0=normal, 
1=lesions involving less than 10% of cortical area, 2=involving 10-30%, 3=involving 31-
50% and 4=involving more than 50%, respectively. ED1 staining representing 
glomerular macrophage infiltration was counted in at least 15 glomerular sections from 
each rat, tubulointerstitial macrophage infiltration in at least 15 randomly selected 
cortical areas per sample observed at x200 magnification, respectively. Due to 
glomerular deposition of platelets as platelet-fibrinogen aggregates, glomerular 
fibrinogen staining was used as indirect indicator for glomerular platelet deposition, and 
glomerular fibrinogen deposition is expressed as the percentage of fibrinogen-positive 
areas in 15 glomeruli from each rat (0-100%) [58]. 
2.5.7 Enzyme-linked immunosorbent assay (ELISA) 
An ELISA technology was used for the assessment of the cytokine TGF-beta1, PAI-
1, protein fibronectin and cGMP. TGF-beta1 was determined by an ELISA sandwich 
methodology. The sample is incubated in a microplate precoated with a capture 
antibody. The antigen in the sample binds with the capture antibody and becomes 
immobilized. After removal of the unbound antigen, enzyme conjugate is added and 
then binds with the immobilized antigen to form a sandwich of antibody-antigen-
antibody/enzyme bound to the microplate. After the unbound antigen or antibody and 
free conjugate are washed off, a chromogenic enzyme substrate is added, and reacts 
with the bound enzyme and produces a color reaction. A quantitative determination of 
antigen or antibody concentrations is obtained by absorbance measurement of the 
colored reaction product using a spectrophotometric microwell reader. 
PAI-1, fibronectin and cGMP were determined by competitive ELISA. In competitive 
ELISA of PAI-1 and fibronectin, the antigen is coated onto the inside wall of the 
microplate. The antigen from the test sample and the antigen coated on the microplate 
compete for a limited number of primary antibody-binding sites. An enzyme-labeled 
secondary antibody is added afterwards. In cGMP ELISA, the antibody is coated onto 
the inside wall of the microplate. The antigen from the test sample and the enzyme-
labeled antigen conjugate compete for a limited number of immobilized antibody-
binding sites. The amount of antigen-antibody-enzyme complex bound to the solid 
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phase (microplate) is inversely related to the concentration of antigen present in the 
sample. After the unbound enzyme antigen conjugate is washed off, chromogenic 
substrate is added. The bound enzyme conjugate reacts with the chromogenic 
substrate and produces a color reaction. A quantitative determination of antigen or 
antibody concentrations is obtained by absorbance measurement of the colored 
reaction product using a spectrophotometric microplate reader. 
2.5.7.1 TGF-beta1 
The TGF-beta1 concentrations were determined in the cell culture supernatant with 
a commercially available ELISA kit (TGF-beta1 Duoset™, R&D Systems, Wiesbaden, 
Germany). A 96-well microplate was coated with 100 µl capture antibody of mouse anti-
TGF-beta1 (2 µg/ml) per well and left overnight at room temperature. Each well was 
aspirated and washed with wash buffer PBST (0.05% Tween20, Boehringer Ingelheim, 
Heidelberg, Germany, in PBS) and blotted against clean paper towels. The plate was 
then blocked by adding block buffer (5% Tween20, 5% Sucrose in PBS) and incubated 
at room temperature for 1 hour. Then the plate was washed again and ready for sample 
addition. Latent TGF-beta1 in the samples should be first activated to the 
immunoreactive form. 100 µl samples were acidified with 20 µl 1 mol/l HCl (Merck, 
Darmstadt, Germany), mixed thoroughly at room temperature for 10 min and then 
neutralized with 20 µl 1.2 mol/l NaOH/0.5 mol/l HEPES buffer. A standard solution of 
recombinant human TGF-beta1 (2000 pg/ml) was diluted with Reagent Diluent (1.4% 
delipidized bovine serum, 0.05% Tween20 in PBS) to form a seven-point standard 
curve using 2-fold serial dilutions from 2000 pg/ml to 0 pg/ml. 100 µl standard and the 
activated sample were pipetted into the precoated microplate and incubated for 2 hours 
at room temperature. Then the aspiration and wash of the microplate were repeated 
again. 100 µl detection antibody (300 ng/ml), chicken anti-human TGF-beta1, were 
added to each well and incubated for 2 hours at room temperature. Then the microplate 
was washed again. 100 µl streptavidin-HRP were added to each well and incubated 20 
min at room temperature in the dark. After washing the microplate, 100 µl substrate 
solution (a mixture of H2O2 and Tetramethylbenzidine) (Biochrom AG, Berlin, Germany) 
were added to each well and incubated for 20 min at room temperature. Finally, 50 µl 
0.18 mol/l H2SO4 (Merck, Darmstadt, Germany) were added to stop the reaction.  And 
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the absorbance of each well was determined at a wavelength of 450 nm immediately. 
The measured values of the samples were computed according to the standard curve.  
2.5.7.2 Fibronectin 
A 96-well microplate was coated and left overnight at 4°C with rat fibronectin antigen 
(200 µg/ml, Sigma, USA), which was dissolved in PBS. Then each well was aspirated 
and blocked by block buffer (10% bovines’ serum albumin in PBST) and incubated for 1 
hour at 37°C. Then the plate was washed with PBST and ready for the addition of 
samples and standards. The samples can be diluted with DMEM. The fibronectin 
standard was diluted to concentrations of 2667, 1334, 667, 333, 167, 83, 42, 21, 10, 5, 
3 and 0 ng/ml. 50 µl standards and samples were incubated with 50 µl rabbit anti-rat 
primary antibody (0.6 µg/ml, Chemicon International, Inc. Temecula, Canada) on 
another non-coated microplate for 1 hour at 37°C. Then 95 µl of the mixture were 
transferred onto the precoated plate and incubated for 1 hour at 37°C. After a wash 
phase, 100 µl peroxidase-conjugated secondary antibody (0.3 µg/ml peroxidase-
conjugated Affini goat anti-rabbit IgG, Dianova, Hamburg, Germany) were added and 
incubated at 37°C for 1 hour. After washing, the OPD substrate-complex was added 
and incubated at room temperature in darkness for 30 min. Finally, the absorbance of 
each well was measured photometrically at a wavelength of 450 nm, and the 
concentrations were computed according to the standard curve.  
2.5.7.3 PAI-1 
In the same way as with the fibronectin ELISA, a 96-well microplate was first coated 
with 100 µl rat PAI-1-antigen (3.6 µg/ml, American diagnostica inc. Greenwich, USA) 
and left overnight at 4°C in PBS. After aspiration of each well, block buffer was added 
and incubated for 1 hour at 37°C. Then the plate was washed with PBST and ready for 
the addition of samples and standards. The samples can be diluted with DMEM. 
Standards were manufactured with concentrations of 1143, 846, 625, 463, 342, 254, 
188, 139, 103, 76, 56, and 0 pg/µl. 50 µl standards and samples were incubated with 50 
µl rabbit anti-rat primary antibody (100 µg/ml, Oxford Biomedical Research, Michigan, 
USA) on another non-coated microplate for 1 hour at 37°C. Then 95 µl of the mixture 
were transferred onto the antigen-coated plate and incubated for 1 hour at 37°C. After a 
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wash phase 100 µl peroxidase-conjugated secondary antibody were added and 
incubated for 1 hour. After washing, the OPD substrate-complex was added and 
incubated at room temperature in darkness for 30 min. Finally, the absorbance of each 
well was measured photometrically at a wavelength of 450 nm, and the concentrations 
were computed according to the standard curve.  
2.5.7.4 cGMP 
The cGMP competitive enzymeimmunoassay system (Amersham, Freiburg, 
Germany) was used in the research. The kit includes novel lysis reagents in order to 
facilitate simple and rapid extraction of cGMP from cells. Lysis reagent 1 hydrolyses cell 
membranes to release intracellular cGMP. Lysis reagent 2 sequesters the key 
component in lysis reagent 1 and ensures cGMP is free for subsequent analysis. The 
assay is based on competition between unlabelled cGMP (from samples) and a fixed 
quantity of peroxidase-labeled cGMP for a limited number of binding sites on a cGMP-
specific antibody. 
2.5.7.4.1 Plasma cGMP 
The assay buffer working solutions and working standards (0, 2, 4, 8, 16, 32, 64, 
128, 256, 512 fmol/well) were prepared as shown in kit. 10 µl of the acetylation reagent 
were added to 100 µl standards and samples. 100 µl rabbit anti-cGMP antibody were 
added to all wells precoated with donkey anti-rabbit IgG except the blank and NSB 
(non-specific binding) wells. Then 50 µl standards and samples were pipetted into the 
appropriate wells. 150 µl of assay buffer were pipetted into the NSB wells. The plate 
was incubated at 3-5°C for 2 hours. Then 100 µl diluted peroxidase-labeled cGMP 
conjugate were added to all wells except the blank. The plate was incubated at 3-5°C 
for 1 hour. Then all wells were aspirated and washed with wash buffer. Immediately, 
200 µl Tetramethylbenzidine substrate were pipetted into all wells. The plate was mixed 
on a microplate shaker for exactly 30 minutes at room temperature. Finally 100 µl of 1 
mol/l H2SO4 were added to all wells to halt the reaction prior to end point determination. 
The optical density can be read at 450 nm within 30 minutes. Finally, the concentrations 
were computed according to the standard curve. 
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2.5.7.4.2 Basal and NO-stimulated cGMP production 
Before the assay, cells would be lysed. After the incubation of culture cells, 20 µl 5% 
dodecytrimethylammonium bromide were added to the cell culture and mixed on a 
microplate shaker for 10 min to facilitate cell lysis. This enabled the total (intra- and 
extracellular) cGMP to be measured. A microscopic evaluation with Trypan blue was 
carried out to check whether the cells were lysed. Lysed cells were then ready for the 
assay. The assay buffer working solutions and working standards (0, 2, 4, 8, 16, 32, 64, 
128, 256, 512 fmol/well) were prepared as shown in kit. 10 µl of the acetylation reagent 
were added to 100 µl standards and samples. 100 µl rabbit anti-cGMP antibody were 
added to all wells precoated with donkey anti-rabbit IgG except the blank and NSB 
wells. Then 50 µl standards and samples were pipetted into the appropriate wells. 50 µl 
diluted lysis reagent 1 and 100 µl diluted lysis reagent 2 were pipetted into the NSB 
wells. The plate was incubated at 3-5°C for 2 hours. Then 100 µl diluted peroxidase-
labeled cGMP conjugate were added to all wells except the blank. The plate was 
incubated at 3-5°C for 1 hour. All wells were aspirated and washed with wash buffer. 
Immediately, 200 µl Tetramethylbenzidine substrate were pipetted into all wells. The 
plate was mixed on a microplate shaker for exactly 30 minutes at room temperature. 
Finally 100 µl of 1 mol/l H2SO4 were added to all wells to halt the reaction prior to end 
point determination. The optical density can be read at 450 nm within 30 minutes. 
Finally, the concentrations were computed according to the standard curve. 
2.5.8 mRNA analysis 
2.5.8.1 RNA isolation by Trizol 
Total RNA was extracted by using Trizol Reagent according to the manufacturer’s 
instructions. 50-100 mg tissue were transferred into 1 ml Trizol reagent and 
homogenized with homogenizer for 30 sec. The samples were then incubated at room 
temperature for 5 min. 200 µl chloroform (Merck, Darmstadt, Germany) were added. 
After 15 sec vigorous vortex of samples, the mixture was incubated at room 
temperature for 3 min and then centrifuged at 14000 rpm and 4°C for 15 min. RNA 
remains exclusively in the upper aqueous phase. The aqueous phase was transferred 
carefully into a fresh tube (about 400-500 µl), and the remainder was discarded. 500 µl 
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isopropyl alcohol (J. T. Baker, Deventer, Holland) were added. The sample was mixed 
by gentle inversion and incubated for 10 min at room temperature. Then the sample 
was centrifuged again at 14000 rpm and 4°C for 10 min. The supernatant was removed 
and the remaining RNA pellet was washed with 1 ml 75% ethanol (Merck, Darmstadt, 
Germany), and then centrifuged at 14000 rpm and 4°C for 5 min. The supernatant was 
removed. The RNA pellet was dried in Laminar Flow for 5-10 min. Then the RNA pellet 
was dissolved in DEPC-treated water and incubated at 60°C in the thermal mixer for 10 
min to ensure total resuspension.  
Two investigation procedures to examine the quality and concentration of the 
isolated RNA content followed. The quality of the RNA was checked on 2% agrose gel 
electrophoresis. 1 µl RNA was dissolved in 9 µl DEPC-treated water. Then 8 µl 
bromine-phenol-blue (Carl Roth GmbH, Karlsruhe, Germany) were added and the 
sample was transferred into gel. The gel was run at 100 volts for 1 hour. Two bands, 
18S and 28S ribosomal RNA bands, can be seen under ultraviolet light. The RNA was 
also spectrophotometrically quantified. 1 µl RNA was mixed with 99 µl DEPC-treated 
water. The zero value attitude of the spectrometer was made with DEPC-treated water. 
The sample was measured at a wavelength of 260 nm against zero. The RNA 
concentration was adjusted to 1 µg/µl with DEPC-treated water. Then the RNA was 
kept at -80°C until further analysis.  
2.5.8.2 Reverse transcription-polymerase chain reaction (RT-PCR) 
RT-PCR is a highly sensitive method for determining gene expression at the RNA 
level and for quantifying the strength of gene expression. “Two-step” RT-PCR was used 
in this research. A cDNA copy is created with reverse transcriptase from the RNA PCR 
Core kit (Roche, Applied Biosystems, New Jersey, USA). 
Table 3: Mixture of reverse transcription components. 
Components Volume (µl) 
MgCl2 4 
10xPCR Buffer 2 
DEPC-treated water 2 
dGTP 2 
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dATP 2 
dTTP 2 
dCTP 2 
RNase Inhibitor 1 
MuLV Reverse Transcriptase 1 
Random Hexamers 1 
RNA 1 (conc. 1 µg/µl) 
The reverse transcription is carried out in a thermocycler using the following 
conditions. The cDNA obtained in this reaction is then used for the subsequent PCR. 
Table 4: Procedure for reverse transcription. 
25°C 10 min 
42°C 45 min 
95°C 5 min 
4°C endlessly 
2.5.8.3 Polymerase chain reaction 
PCR is a method for oligonucleotide primer-directed enzymatic amplification of a 
specific DNA sequence of interest. The PCR product is amplified from a DNA template 
using a heat-stable DNA polymerase and an automated thermocycler to put the 
reaction through 30 or more cycles of denaturing, annealing of primers and 
polymerization. Quantitative analysis of changes in molecular targets with PCR plays a 
key role in scientific research.  
The amount of PCR product increases logarithmically in the first few PCR cycles 
before reaching a plateau. To ensure accurate quantification of the sample 
concentration, only these first cycles should be considered. The later PCR cycles, 
which are usually run to ascertain the final amount of PCR product, do not easily permit 
to drawn conclusions as to starting concentrations. In conventional PCR, an endpoint 
analysis is carried out in the plateau phase of the PCR by examining the products by 
the staining of the sample separated by gel electrophoresis. In this research, PCR was 
checked with a LightCycler System called Real-time PCR [62, 63]. Real-time PCR 
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refers to the continuous monitoring of the progress of the amplification during the whole 
PCR reaction and allows measurements to be made during the log-linear phase of a 
PCR. Utilization of a dsDNA-binding dye, SYBR Green I (Roche Diagnostics GmbH, 
Mannheim, Germany), is more specific since it only fluoresces when bound to dsDNA. 
The LightCycler System typically measures fluorescence once every cycle, to monitor 
the increase in PCR product formation.  
The LightCycler System is capable of providing sequence confirmation of the 
amplified product through an innovative function called melting curve analysis. Each 
dsDNA product has its own specific melting temperature (Tm). Checking the Tm of a 
PCR product can thus be compared with analyzing a PCR product by length in gel 
electrophoresis to examine the purification.  
A relative quantification was used, which is based on the relative expression of a 
target gene versus a reference gene, GAPDH in this study. Amplification is described 
as N=N0*E?CP (N: number of amplified molecules; N0: initial number of molecules; E: 
amplification efficiency; ?CP: crossing point deviation expressing as ?CP=CPtarget-
CPGAPDH) [64]. In this quantification method, CP is defined as the point at which the 
fluorescence rises appreciably above the background fluorescence. Finally the N0 of 
samples were calculated and compared.  
A mastermix of the following reaction components was prepared: 
Table 5: Mixture of PCR components. 
Components Volume (µl) 
MgCl2 1.6 
DEPC-treated water 11.4 
Template (sense) 1.5 
Template (antisense) 1.5 
SYBR Green 2.0 (Conc. 0.5 µg/µl) 
cDNA 2.0 
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The template used (TIB Molbiol, Berlin, Germany): 
Table 6: Templates of PCR. 
Template Sequence 
Annealing/Melting 
Temperature 
GAPDH 
sense 
antisense 
 
5´-CCATCTTCCAGGAGCGAGAT-3´ 
5´-GATGACCTTGCCCACAGCCT-3´ 
59°C/86°C 
eNOs 
sense 
antisense 
 
5´- TCCAGTAACACAGACAGTGC -3´ 
5´- CAGGAAGTAAGTGAGAGCCTG -3´ 
61°C/88°C 
iNOS 
sense 
antisense 
 
5´- GCAGAATGTGACCATCATGG -3´ 
5´- ACAACCTTGGTGTTGAAGGC -3´ 
60°C/86°C 
alpha1sGC 
sense 
antisense 
 
5´- CCACATCAACACAGGCTAAT -3´ 
5´- GAAGTGCAAGGTTCAGTCTC -3´ 
62°C/86°C 
beta1sGC 
sense 
antisense 
 
5´- CGGATGCCACGGTATTGTCT -3´ 
5´- CTCCTGGCTTGACGCACATT -3´ 
62°C/84°C 
P-selectin 
sense 
antisense 
 
5´- ACCATGACGTGTATCCAGCC -3´ 
5´- CCTTCGTCACACATGAACTG -3´ 
61°C/79°C 
TGF-beta1 
sense 
antisense 
 
5´-GGTGGCAGGCGAGAGCGCTGA-3´ 
5´-GGCATGGTAGCCCTTGGGCT-3´ 
64°C/86°C 
PAI-1 
sense 
antisense 
 
5´-CAGCATGTGGTCCAGGCCTCCAAA-3´ 
5´-TGTGCCGCTCTCGTTCACCTCGATCT-3´ 
64°C/84°C 
Fibronectin 
sense 
antisense 
 
5´-GGTCCAAATCGGTCATGTTCCCA-3´ 
5´-CGTAATGGGAAACCGTGTAAGGG-3´ 
64°C/86°C 
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2.6 Statistical analysis 
All values are expressed as mean ± standard error of the mean (SEM). Statistics 
were analyzed with SPSS 11.0. For normal distributive data analysis, one-way analysis 
of variance (ANOVA) and an unpaired student’s t-test were used. Regarding the 
abnormal distributive data, statistical analysis was performed using a Mann-Whitney-U-
test. A p value <0.05 was considered significant. 
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3 Results 
3.1 Blood pressure, bleeding time and plasma cGMP levels in acute anti-thy1 
glomerulonephritis (injury phase and matrix expansion phase) 
In this study, similar results were found in blood pressure, bleeding time and plasma 
cGMP levels of the injury phase and the matrix expansion phase in acute anti-thy1 
glomerulonephritis. In the interest of simplicity, they are presented together. 
3.1.1 Systolic blood pressure 
As shown in Figure 3, systolic blood pressure was normal in the control (123±1 
mmHg) and untreated aGN groups (118±2 mmHg). The intake of Bay 41-2272 
significantly decreased systolic blood pressure (101±3 mmHg). 
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Figure 3: Effects of Bay 41-2272 (+Bay 41-2272) on systolic blood pressure in acute 
anti-thy1 glomerulonephritis (aGN). Normal control animals (Control) were injected with 
PBS. Blood pressure was measured in conscious rats using tail cuff. (**p<0.01 vs. aGN 
and Control) 
3.1.2 Bleeding time 
As shown in Figure 4, the bleeding time was significantly prolonged by Bay 41-2272 
treatment (471±41 sec) as compared to the control and the aGN groups (268±21 sec 
and 298±36 sec, respectively).  
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Figure 4: Effects of Bay 41-2272 (+Bay 41-2272) on bleeding time in acute anti-thy1 
glomerulonephritis (aGN). Bleeding was induced by a standard tail incision (10 mm long 
and 1 mm deep) in anesthetized animals. (**p<0.01 vs. aGN and Control) 
3.1.3 Plasma cGMP levels 
As shown in Figure 5, plasma cGMP levels were significantly higher in the untreated 
aGN group than those in the normal controls (4130±650 fmol/ml vs. 2120±260 fmol/ml), 
and were elevated significantly further by Bay 41-2272 treatment (6610±810 fmol/ml). 
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Figure 5: Effects of Bay 41-2272 (+Bay 41-2272) on plasma cGMP levels in acute 
anti-thy1 glomerulonephritis (aGN). Normal control animals (Control) were injected with 
PBS. (**p<0.01 and *p<0.05 vs. Control, #p<0.05 vs. aGN) 
 
Summing up, Bay 41-2272 treatment caused a decrease in systolic blood pressure, 
a prolongation of bleeding time and an increase in the plasma cGMP levels, which 
proves the in vivo bioavailability of the drug through stimulating cGMP synthesis. 
3.2 Protocol 1: NO-cGMP signaling in the injury phase 1 day after induction of 
acute anti-thy1 glomerulonephritis 
3.2.1 Body weight 
The aGN+Bay 41-2272 group was treated for 6 days before and 1 day after the 
induction of acute anti-thy1 glomerulonephritis. The experiment was ended 1 day after 
disease induction. There was no difference in the body weight at the end of the 
experiment among the three groups (Control 253±3 g, aGN 250±5 g and aGN+Bay 41-
2272 255±7 g). 
3.2.2 Proteinuria 
The proteinuria of diseased rats was significantly higher than that in the control 
group (14±2 mg/day, p<0.01 vs. aGN and aGN+Bay 41-2272). Treatment with Bay 41-
2272 before anti-thy1 antibody-induced mesangial cell lysis reduced proteinuria slightly, 
but not significantly, when compared to the aGN group (31±4 mg/day vs. 53±10 mg/day, 
p>0.05).  
3.2.3 Mesangial cell lysis 
As shown in Figure 6, anti-thy1 antibody injection resulted in a rapid drop in 
glomerular cell number. Cell nuclei counts averaged 56.3±1.1 per glomerular section in 
the control group, whereas the aGN group’s and the aGN+Bay 41-2272 group’s cell 
counts were significantly reduced to 44±1.1 and 44.3±1.1 per glomerular section, 
respectively. There was no difference between the aGN group and the aGN+Bay 41-
2272 group. This result indicates that Bay 41-2272 has no effect on mesangial cell 
injury 1 day after anti-thy1 glomerulonephritis induction.  
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Figure 6: Effects of Bay 41-2272 (+Bay 41-2272) on glomerular nuclei count 
indicating mesangial cell lysis 1 day after induction of acute anti-thy1 glomerulonephritis 
(aGN). Normal control rats (Control) were injected with PBS. (***p<0.001 vs. Control) 
3.2.4 Glomerular iNOS-NO pathway 
As shown in Figure 7, glomerular iNOS mRNA expression increased significantly in 
the aGN group (263±38%) as compared to the control group (100±28%). This increase 
was not significantly changed in the Bay 41-2272 treated group (226±26%). 
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Figure 7: Effects of Bay 41-2272 (+Bay 41-2272) on glomerular iNOS mRNA 
expression 1 day after induction of acute anti-thy1 glomerulonephritis (aGN). Normal 
control animals (Control) were injected with PBS. mRNA was analyzed by a real-time 
PCR method using GAPDH as housekeeping gene. mRNA is shown as a percentage of 
the normal control group. (**p<0.01 vs. Control) 
 
As shown in Figure 8, glomerular NO production was in line with the iNOS mRNA 
expression. Compared to the control group (2.1±0.3 nmol/ml), the basal NO synthesis 
of isolated glomeruli was significantly elevated in the aGN group (6.9±0.5 nmol/ml) and 
the aGN+Bay 41-2272 group (6.9±1.7 nmol/ml) 1 day after disease induction. LPS 
stimulated the glomerular NO production significantly in the aGN group (49.1±4.7 
nmol/ml) and the aGN+Bay 41.2272 group (50.6±8.8 nmol/ml), in contrast to the control 
group (9.3±0.9 nmol/ml). And there was no difference between the aGN and the Bay 
41-2272-treated aGN group. 
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Figure 8: Effects of Bay 41-2272 (+Bay 41-2272) on glomerular basal and LPS-
stimulated NO production 1 day after induction of acute anti-thy1 glomerulonephritis 
(aGN). Normal control animals (Control) were injected with PBS. Nitrite as indicator of 
NO production was determined by the Griess reaction. Glomeruli were harvested from 
individual animals and cultured at a density of 2000 per ml for 48 hours. (***p<0.001 
and **p<0.01 vs. Control) 
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3.2.5 Glomerular eNOS-NO-cGMP signaling cascade 
As shown in Figure 9, there was no difference in eNOS mRNA expression among 
the three groups (control 100±15%, aGN 145±23%, aGN+Bay 41-2272 100±14%, 
P>0.05). The induction of anti-thy1 glomerulonephritis did not significantly change 
eNOS expression. 
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Figure 9: Effects of Bay 41-2272 (+Bay 41-2272) on glomerular eNOS mRNA 
expression 1 day after induction of acute anti-thy1 glomerulonephritis (aGN). Normal 
control animals (Control) were injected with PBS. mRNA was analyzed by a real-time 
PCR method using GAPDH as housekeeping gene. mRNA is shown as a percentage of 
the normal control group. 
 
As shown in Figure 10, compared to the control group (alpha1 sGC 100±21% and 
beta1 sGC 100±22%), sGC mRNA expression was reduced significantly by 90% after 
anti-thy 1 antibody injection (aGN: alpha1 sGC 10±2% and beta1 sGC 13±2%, 
aGN+Bay 41-2272: alpha1 sGC 6±2% and beta1 sGC 10±2%). 
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Figure 10: Effects of Bay 41-2272 (+Bay 41-2272) on glomerular alpha1 sGC and 
beta1 sGC mRNA expression 1 day after induction of acute anti-thy1 glomerulonephritis 
(aGN). Normal control animals (Control) were injected with PBS. mRNA was analyzed 
by a real-time PCR method using GAPDH as housekeeping gene. mRNA is shown as a 
percentage of the normal control group.(***p<0.001 vs. Control) 
 
As shown in Figure 11, corresponding to sGC mRNA expression, basal and NO-
stimulated glomerular cGMP levels were significantly depressed in the untreated 
diseased animals as compared to normal controls (basal cGMP levels: 10±1 fmol/well 
vs. 27±5 fmol/well, NO-stimulated cGMP levels: 34±11 fmol/well vs. 143±23 fmol/well, 
both p<0.01 vs. Control). Treatment with Bay 41-2272 had no significant influence on 
the glomerular cGMP levels (basal cGMP production 12±1 fmol/well and NO-stimulated 
cGMP production 25±3 fmol/well). 
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Figure 11: Effects of Bay 41-2272 (+Bay 41-2272) on basal and DEA/NO stimulated 
glomerular cGMP production 1 day after induction of acute anti-thy1 glomerulonephritis 
(aGN). Normal control animals (Control) were injected with PBS. cGMP generation was 
measured by ELISA in glomeruli harvested from individual animals in the presence or 
absence of the NO donor DEA/NO. (**p<0.01 vs. Control) 
 
Taken together, the results from protocol 1 consistently demonstrate that the 
expression and activity of the NO-cGMP pathway are dramatically impaired one day 
after anti-thy1 glomerulonephritis induction. Treatment with Bay 41-2272 could not 
stimulate glomerular cGMP synthesis and hence was unable to affect the mesangial 
cell lysis in the injury phase of acute anti-thy1 glomerulonephritis. 
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3.3 Protocol 2: NO-cGMP signaling in the matrix expansion phase 7 days after 
induction of acute anti-thy1 glomerulonephritis 
3.3.1 Body weight 
Bay 41-2272 treatment was begun 1 day after and continued 7 days after the 
induction of acute anti-thy1 glomerulonephritis. The experiment ended 7 days after 
disease induction. There was no difference in the body weight at the end of the 
experiment among the three groups (Control 231±14 g, aGN 240±11 g and aGN+Bay 
41-2272 240±12 g). 
3.3.2 Proteinuria 
As shown in Figure 12, in contrast to the normal controls (16±4 mg/day), proteinuria 
was significantly elevated in the diseased rats (aGN 165±10 mg/day, aGN+Bay 41-
2272 110±18 mg/day). Bay 41-2272 treatment significantly reduced proteinuria as 
compared to untreated nephritic rats. 
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Figure 12: Effects of Bay 41-2272 (+Bay 41-2272) on proteinuria 7 days after 
induction of acute anti-thy1 glomerulonephritis (aGN). Normal control animals (Control) 
were injected with PBS. Urine was collected for 24 hours using metabolic cages. 
(*p<0.05 vs. aGN) 
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3.3.3 Markers of glomerular matrix expansion 
As shown in Figure 13, compared to the control group (Control: matrix score 1.1±0.1, 
TGF-beta1 78±13 pg/ml, fibronectin 7766±497 ng/ml and PAI-1 399±29 ng/ml), 
diseased animals in the matrix expansion phase were characterized by significant 
glomerular matrix expansion and TGF-beta1 overexpression (aGN: matrix score 
2.9±0.1, TGF-beta1 817±66 pg/ml, fibronectin 69587±2886 ng/ml and PAI-1 1368±40 
ng/ml). Treatment with Bay 41-2272 limited glomerular matrix expansion significantly 
(aGN+Bay 41-2272: matrix score 2.6±0.1, TGF-beta1 603±49 pg/ml, fibronectin 
45668±2513 ng/ml and PAI-1 1156±53 ng/ml, p<0.05 vs. aGN for all parameters). 
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Figure 13: Effects of Bay 41-2272 (+Bay 41-2272) on markers of glomerular matrix 
expansion, including matrix score, TGF-beta1, fibronectin and PAI-1 production, 7 days 
after induction of acute anti-thy1 glomerulonephritis (aGN). Normal control animals 
(Control) were injected with PBS. Matrix expansion was scored on PAS-stained slides. 
Glomeruli were harvested from individual animals and cultured at a density of 2000 per 
ml for 48 hours. (***p<0.001, **p<0.01, *p<0.05 vs. aGN) 
3.3.4 Glomerular eNOS-NO-cGMP signaling cascade 
As shown in Figure 14, compared to the aGN group (72±10%), Bay 41-2272 
treatment significantly up-regulated eNOS mRNA expression (125±20%). There was no 
significant difference in eNOS mRNA between the control group (100±10%) and the 
untreated aGN group. 
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Figure 14: Effects of Bay 41-2272 (+Bay 41-2272) on glomerular eNOS mRNA 
expression 7 days after induction of acute anti-thy1 glomerulonephritis (aGN). Normal 
control animals (Control) were injected with PBS. mRNA was analyzed by a real-time 
PCR method using GAPDH as housekeeping gene. mRNA is shown as a percentage of 
the normal control group. (*p<0.05 vs. aGN) 
As shown in Figure 15, compared to the normal controls (alpha1 sGC 100±14% and 
beta1 sGC 100±15%), sGC mRNA expression in the untreated aGN group (alpha1 sGC 
563±76% and beta1 sGC 330±31%) increased significantly after disease induction. 
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Treatment with Bay 41-2272 further up-regulated sGC mRNA expression (alpha1 sGC 
1758±544% and beta1 sGC 1218±463%) to a greater extent than in the aGN group. As 
is consistent with the sGC mRNA expression, basal and NO-stimulated glomerular 
cGMP production was significantly elevated in nephritic animals (382±156 fmol/well and 
38011±17528 fmol/well) as compared to normal controls (basal cGMP production: 16±3 
fmol/well, NO-stimulated cGMP production: 195±33 fmol/well). Although basal 
glomerular cGMP production was similar in treated (381±98 fmol/well) and untreated 
nephritic animals, glomerular NO-stimulated cGMP production was significantly further 
increased in the Bay 41-2272-treated animals (181969±114910 fmol/well). 
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Figure 15: Effects of Bay 41-2272 (+Bay 41-2272) on glomerular sGC mRNA 
expression and sGC activity to produce cGMP 7 days after induction of acute anti-thy1 
glomerulonephritis (aGN). Normal control animals (Control) were injected with PBS. 
mRNA was analyzed by a real-time PCR method using GAPDH as housekeeping gene. 
mRNA is shown as a percentage of the normal control group. cGMP generation was 
measured by ELISA in glomeruli harvested from individual animals in the presence or 
absence of the NO donor DEA/NO. (***p<0.001 and *p<0.05 vs. Control, #p<0.05 vs. 
aGN) 
3.3.5 Mechanisms of Bay 41-2272’s renoprotective effects 
3.3.5.1 Blood pressure 
As shown in Figure 3, Bay 41-2272 reduced systolic blood pressure significantly, as 
compared to control and untreated nephritic animals. 
3.3.5.2 TGF-beta1 production in vitro 
As shown in Figure 16, 48 hours of exposure of glomeruli to Bay 41-2272 induced a 
dose-dependent decrease in glomerular TGF-beta1 production. In normal glomeruli, 0.1 
µM, 1 µM, 5 µM and 10 µM Bay 41-2272 reduced TGF-beta1 production by 16%, 24%, 
28% and 26%, and in day 7 anti-thy1 nephritic glomeruli, TGF-beta1 production were 
reduced by 10%, 15%, 25% and 21%, respectively.  
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Figure 16: In vitro effects of Bay 41-2272 on TGF-beta1 production in glomeruli 
isolated from control and nephritic rats 7 days after induction of acute anti-thy1 
glomerulonephritis (aGN). Normal control animals (Control) were injected with PBS. 
Glomeruli were cultured at a density of 2000 per ml for 48 hours in the presence of Bay 
41-2272 in a concentration sequence of 0.1 µM, 1 µM, 5 µM and 10 µM. (*p<0.05 vs. 
glomeruli of Control and aGN without Bay 41-2272) 
3.3.5.3 Glomerular platelet deposition 
As shown in Figure 17, fibrinogen staining was hardly found in the control group. In 
contrast to the untreated aGN group (45±6% staining-positive area per glomerulus), 
Bay 41-2272 treatment (29±3% staining-positive area per glomerulus) significantly 
reduced fibrinogen deposition, which indicates platelet aggregation in the glomeruli. 
Combined with the prolonged bleeding time, this indicates that Bay 41-2272 has an 
anti-platelet effect through elevated cGMP synthesis. 
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Figure 17: Effects of Bay 41-2272 (+Bay 41-2272) on glomerular fibrinogen 
deposition 7 days after induction of acute anti-thy1 glomerulonephritis (aGN). Normal 
control animals (Control) were injected with PBS. Glomerular fibrinogen deposition is 
expressed as the percentage of fibrinogen-positive area per glomerular cross-section. 
(*p<0.05 vs. aGN) 
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3.3.5.4 Glomerular macrophage infiltration 
As shown in Figure 18, the nephritic groups had more glomerular macrophage 
infiltration than the control group (0.8±0.2 cells per glomerular section). Glomerular 
macrophage infiltration was significantly inhibited by Bay 41-2272 treatment (6.2±0.5 
cells per glomerular section), in contrast to the aGN group (9.2±1.2 cells per glomerular 
section). Although there was no significant difference in P-selectin mRNA expression 
among the three groups, Bay 41-2272 treatment (85±12%) slightly inhibited glomerular 
P-selectin mRNA expression, as compared to the aGN group (132±25%). 
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Figure 18: Effects of Bay 41-2272 (+Bay 41-2272) on glomerular ED1-positive cell 
infiltration and P-selectin mRNA expression 7 days after induction of acute anti-thy1 
glomerulonephritis (aGN). Normal control animals (Control) were injected with PBS. 
Glomerular macrophage infiltration is expressed as number of ED1-positive cells per 
glomerular cross-section. mRNA was analyzed by a real-time PCR method using 
GAPDH as housekeeping gene. mRNA is shown as a percentage of the normal control 
group. (*p<0.05 vs. aGN) 
Taken together, the results of protocol 2 show that the NO-cGMP pathway is 
significantly up-regulated in the matrix expansion phase of acute anti-thy1 
glomerulonephritis. Bay 41-2272 treatment further increased sGC expression and 
activity to produce cGMP, which limited the fibrotic parameters characterized in the 
matrix expansion phase of acute anti-thy1 glomerulonephritis. 
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3.4 Protocol 3: NO-cGMP signaling 16 weeks after induction of anti-thy1-induced 
chronic glomerulosclerosis (progression phase) 
3.4.1 Body weight 
Treatments with Bay 41-2272 and hydralazine were started 7 days after the 
induction of chronic-progressive anti-thy1 glomerulosclerosis (cGS). The experiment 
ended 16 weeks after disease induction. There was no difference in body weights at the 
beginning and the end of the experiment among the three cGS groups. At the end of 
the experiment, the final body weights in all diseased groups were significantly lower 
than those in the control groups. 
Table 7: Effects of Bay 41-2272 (+Bay 41-2272) and hydralazine (+Hydralazine) on 
rats’ body weights at the beginning and the end of chronic-progressive anti-thy1 
glomerulosclerosis (cGS). Treatments were started 7 days after injection of anti-thy1 
antibody into uni-nephrectomized rats. Non-diseased animals without (2-K Control) or 
with uni-nephrectomy (1-K Control) received a PBS injection. (*p<0.05 vs. Control)  
Groups 2-K Control 1-K Control cGS cGS+Bay 41-2272 cGS+Hydralazine 
Begin 256±3 g 230±8 g 220±2 g 224±2 g 219±3 g 
End 575±21 g 570±24 g 488±15 g* 482±11 g* 464±13 g* 
3.4.2 Systolic blood pressure 
As shown in Figure 19, the model of anti-thy1-induced chronic glomerulosclerosis 
was characterized by a significant increase in systolic blood pressure 8 weeks and 16 
weeks after disease induction (134±2 mmHg and 135±1 mmHg, respectively), 
compared to 2-K Control (129±2 mmHg and 122±4 mmHg) and 1-K Control (122±4 
mmHg and 122±5 mmHg). Bay 41-2272 treatment lowered blood pressure significantly 
to 116±3 mmHg in week 8 and 116±2 mmHg in week 16 after anti-thy1 antibody-
injection, in comparison to the untreated cGS groups. Hydralazine administration 
reduced also systolic blood pressure significantly to 109±4 mmHg and 110±3 mmHg, 
respectively. Due to the absence of a significant difference between the Bay 41-2272-
treated group and the hydralazine-treated group, hydralazine was a good control drug 
to observe the blood pressure-independent effect of Bay 41-2272. 
                                                                                                                                 3 Results 
 - 56 - 
2-K
 Co
ntro
l
1-K
 Co
ntro
l cGS
cGS
+Ba
y 41
-227
2
cGS
+Hy
dra
lazi
neB
lo
od
 p
re
ss
ur
e 
(m
m
H
g)
 (8
 w
ee
ks
)
0
40
80
120
160
***
2-K
 Co
ntro
l
1-K
 Co
ntro
l cGS
cGS
+Ba
y 41
-227
2
cGS
+Hy
dra
lazi
neB
lo
od
 p
re
ss
ur
e 
(m
m
H
g)
 (1
6 
w
ee
ks
)
0
40
80
120
160
*** *** ***
** **
 
Figure 19: Effects of Bay 41-2272 (+Bay 41-2272) and hydralazine (+Hydralazine) 
on systolic blood pressure 8 weeks and 16 weeks after induction of chronic-progressive 
anti-thy1 glomerulosclerosis (cGS). Treatments were started 7 days after injection of 
anti-thy1 antibody into uni-nephrectomized rats. Non-diseased animals without (2-K 
Control) or with uni-nephrectomy (1-K Control) received a PBS injection. Blood 
pressure was measured in conscious animals using a tail cuff method. (**p<0.01 vs. 
Control, ***p<0.001 vs. cGS) 
3.4.3 Proteinuria 
As shown in Figure 20, all diseased rats were randomized at the beginning of the 
protocol, so that every diseased group had similar proteinuria (cGS 148±8 mg/day, 
cGS+Bay 41-2272 146±7 mg/day, cGS+Hydralazine 148±10 mg/day), and proteinuria 
was significantly elevated in all diseased groups, in contrast to the 2-K and 1-K Controls 
(20±4 mg/day and 17±2 mg/day). During the experiment, proteinuria gradually 
increased in the three diseased groups, indicating a progressive chronic 
glomerulosclerosis model. At the end of the protocol, proteinuria was reduced slightly 
by Bay 41-2272 treatment (cGS+Bay 41-2272 422±42 mg/day, p>0.05 vs. cGS 476±56 
mg/day and cGS+Hydralazine 451±70 mg/day), although not significantly.  
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Figure 20: Effects of Bay 41-2272 (+Bay 41-2272) and hydralazine (+Hydralazine) 
on time course of proteinuria after induction of chronic-progressive anti-thy1 
glomerulosclerosis (cGS). Treatments were started 7 days after injection of anti-thy1 
antibody into uni-nephrectomized rats. Non-diseased animals without (2-K Control) or 
with uni-nephrectomy (1-K Control) received a PBS injection. Urine was collected for 24 
hours using metabolic cages. 
3.4.4 Markers of tubulointerstitial matrix accumulation 
3.4.4.1 Matrix score 
As shown in Figure 21, compared to the 2-K (0.04±0.004) and the 1-K Control 
(0.1±0.02), injection of anti-thy1 antibody induced significant tubulointerstitial matrix 
protein deposition in the cGS group (2.49±0.22). Bay 41-2272 treatment reduced 
tubulointerstitial matrix protein accumulation significantly (-35.1%), in contrast to 
hydralazine treatment, which lowered matrix protein accumulation only slightly but not 
significantly (-9.2%), suggesting that Bay 41-2272 had a blood pressure-independent 
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effect on tubulointerstitial matrix protein accumulation. 
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Figure 21: Effects of Bay 41-2272 (+Bay 41-2272) and hydralazine (+Hydralazine) 
on tubulointerstitial matrix protein accumulation 16 weeks after induction of chronic-
progressive anti-thy1 glomerulosclerosis (cGS). Treatments were started 7 days after 
injection of anti-thy1 antibody into uni-nephrectomized rats. Non-diseased animals 
without (2-K Control) or with uni-nephrectomy (1-K Control) received a PBS injection. 
Matrix expansion was scored on PAS-stained slides. (**p<0.01 vs. cGS, #p<0.05 vs. 
cGS+Hydralazine) 
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Figure 22: Effects of Bay 41-2272 and hydralazine on the histological picture 16 
weeks after induction of chronic-progressive anti-thy1 glomerulosclerosis (cGS). 
Treatment was started 7 days after injection of anti-thy1 antibody into uni-
nephrectomized rats. Shown are characteristic PAS-stained renal sections from A) a 
non-diseased animal without (2-K Control) and B) with uni-nephrectomy (1-K Control), 
and C) an animal with anti-thy1-induced chronic glomerulosclerosis without treatment 
and with Bay 41-2272 (D) or with hydralazine treatment (E) (Magnification x200). 
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3.4.4.2 Protein and mRNA expression of TGF-beta1, fibronectin and PAI-1  
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Figure 23: Effects of Bay 41-2272 (+Bay 41-2272) and hydralazine (+Hydralazine) 
on tubulointerstitial TGF-beta1, fibronectin and PAI-1 protein and mRNA expression 16 
weeks after induction of chronic-progressive anti-thy1 glomerulosclerosis (cGS). 
Treatments were started 7 days after injection of anti-thy1 antibody into uni-
nephrectomized rats. Non-diseased animals without (2-K Control) or with uni-
nephrectomy (1-K Control) received a PBS injection. Matrix protein production was 
determined in extensively minced individual cortical tissues cultured at a density of 10 
mg/ml for 48 hours. mRNA was analyzed by a real-time PCR method using GAPDH as 
housekeeping gene. mRNA is shown as a percentage of the untreated chronic anti-thy1 
animals. (***p<0.001, **p<0.01 and *p<0.05 vs. cGS, ###p<0.001 and #p<0.05 vs. 
cGS+Hydralazine) 
As shown in Figure 23, tubulointerstitial TGF-beta1, fibronectin and PAI-1 
expression closely followed the changes seen in histological matrix deposition. 
Compared to 1-K Control animals (TGF-beta1 58±4 pg/ml, fibronectin 1182±145 ng/ml 
and PAI-1 108±12 ng/ml), the untreated cGS group was characterized by marked 
increases in the tubulointerstitial protein expression of TGF-beta1 (297±24 pg/ml), 
fibronectin (7296±760 ng/ml) and PAI-1 (240±12 ng/ml). The mRNA expression of TGF-
beta1, fibronectin and PAI-1 was elevated 9.4-, 10.9- and 13.1-fold, respectively, in 
contrast to 1-K Control animals (TGF-beta1 12.84±2.79%, fibronectin 9.88±1.49% and 
PAI-1 6.58±0.69%). Treatment with Bay 41-2272 significantly reduced tubulointerstitial 
protein and mRNA expression of TGF-beta1 (-40.6%, -37.3%), fibronectin (-50.6%, -
59.7%) and PAI-1 (-15.1%, -55.2%), respectively, while treatment with hydralazine only 
slightly and not significantly lowered the tubulointerstitial protein and mRNA expression 
of TGF-beta1 (-7.1%, -21%), fibronectin (-18.2%, -28%) and PAI-1 (-6.6%, -26.8%) in 
the chronic anti-thy1 animals. 
3.4.5 Markers of glomerular matrix accumulation 
As shown in Figure 24, the glomerular matrix protein expression in anti-thy1-induced 
chronic glomerulosclerosis was characterized by a significant increase in the 
histological matrix score (1.95±0.14) and protein expression of TGF-beta1 (173±24 
pg/ml), fibronectin (11229±1255 ng/ml) and PAI-1 (351±32 ng/ml), compared to the 1-K 
Control (matrix score 0.86±0.03, TGF-beta1 53±9 pg/ml, fibronectin 2372±511 ng/ml 
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and PAI-1 208±25 ng/ml). While Bay 41-2272 significantly lowered histological matrix 
accumulation (-35.4%) and TGF-beta1 (-28.3%) and fibronectin protein expression (-
50.3%), treatment with hydralazine did not significantly affect glomerular matrix protein 
expression and accumulation (matrix score -4.6%, TGF-beta1 -1.7%, fibronectin -1.8% 
and PAI-1 +0.3%). Glomerular PAI-1 protein expression was also reduced by Bay 41-
2272 (-14.8%), but this did not reach statistical significance. 
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Figure 24: Effects of Bay 41-2272 (+Bay 41-2272) and hydralazine (+Hydralazine) 
on glomerular matrix protein accumulation and TGF-beta1, fibronectin and PAI-1 
protein expression 16 weeks after induction of chronic-progressive anti-thy1 
glomerulosclerosis (cGS). Treatments were started 7 days after injection of anti-thy1 
antibody into uni-nephrectomized rats. Non-diseased animals without (2-K Control) or 
with uni-nephrectomy (1-K Control) received a PBS injection. Matrix expansion was 
scored on PAS-stained slides. Glomeruli were harvested from individual animals and 
cultured at a density of 2000 per ml for 48 hours. (***p<0.001, **p<0.01 and *p<0.05 vs. 
cGS, ###p<0.001 vs. cGS+Hydralazine) 
3.4.6 Markers of renal function 
As shown in Figure 25, plasma creatinine, urea levels, creatinine clearance and 
hematocrit were analyzed as markers of renal function. Animals with chronic anti-thy1 
glomerulosclerosis showed significant increases in plasma creatinine (cGS: 1.89±0.38 
vs. 1-K Control: 0.47±0.01 mg/dl) and urea levels (cGS: 187±45 vs. 1-K Control: 51±3 
mg/dl), while creatinine clearances (cGS: 0.25±0.04 vs. 1-K Control: 0.52±0.02 
ml/min/100g body weight) and blood hematocrit levels (cGS: 41±2% vs. 1-K Control: 
48±1%) were significantly decreased. Corresponding to the histological and molecular 
results on renal matrix expansion, treatment with Bay 41-2272 significantly lowered 
plasma creatinine levels (0.74±0.08 mg/dl) and urea levels (85±10 mg/dl), while 
creatinine clearances (0.48±0.06 ml/min/100g body weight) and blood hematocrit levels 
(46±1%) were preserved. In contrast, renal function was not significantly affected by 
hydralazine treatment (plasma creatinine 1.51±0.42 mg/dl, plasma urea 139±25 mg/dl, 
and creatinine clearance 0.34±0.05 ml/min/100 g body weight and hematocrit 40±2%). 
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Figure 25: Effects of Bay 41-2272 (+Bay 41-2272) and hydralazine (+Hydralazine) 
on markers of renal function 16 weeks after induction of chronic-progressive anti-thy1 
glomerulosclerosis (cGS). Treatment was started 7 days after injection of anti-thy1 
antibody into uni-nephrectomized rats. Non-diseased animals without (2-K Control) or 
with uni-nephrectomy (1-K Control) received a PBS injection. (**p<0.01 and *p<0.05 vs. 
cGS, #p<0.05 vs cGS+Hydralazine) 
3.4.7 Tubulointerstitial eNOS-NO-cGMP signaling cascade 
As shown in Figure 26, although there was no significant difference among the three 
diseased groups (cGS: 100±7%, cGS+Bay 41-2272: 132±14% and cGS+Hydralazine: 
100±15%), in comparison to the 1-K and 2-K Control groups (70±12% and 73±9%), 
eNOS mRNA expression was elevated in diseased animals, especially in the cGS+Bay 
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41-2272 group. 
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Figure 26: Effects of Bay 41-2272 (+Bay 41-2272) and hydralazine (+Hydralazine) 
on tubulointerstitial eNOS mRNA expression 16 weeks after induction of chronic-
progressive anti-thy1 glomerulosclerosis (cGS). Treatments were started 7 days after 
injection of anti-thy1 antibody into uni-nephrectomized rats. Non-diseased animals 
without (2-K Control) or with uni-nephrectomy (1-K Control) received a PBS injection. 
mRNA was analyzed by a real-time PCR method using GAPDH as housekeeping gene. 
mRNA is shown as a percentage of the untreated chronic anti-thy1 animals. (*p<0.05 vs. 
Control) 
 
As shown in Figure 27, in comparison to the 2-K (32±16% and 34±7%) and 1-K 
(39±16% and 29±7%) Control groups, anti-thy1-induced chronic glomerulosclerosis 
showed a marked 2.8-fold and 3.2-fold increase in the mRNA expression of the 
tubulointerstitial alpha1- and beta1 sGC. While basal tubulointerstitial cGMP production 
did not differ between the untreated diseased group (19±1.48 fmol/well) and the control 
groups (2-K 24±2 fmol/well and 1-K 22.5±4.5 fmol/well), the NO-stimulated cGMP 
production was 2.7-fold higher in the chronic anti-thy1 group than in 2-K Control 
(115±16 fmol/well) and 1-K Control group (92±6 fmol/well). Compared to the untreated 
diseased animals, administration of Bay 41-2272 did not significantly alter the 
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expression of the sGC (alpha1 80±16% and beta1 95±17%), but resulted in a 
significantly higher NO-stimulated tubulointerstitial cGMP production (534±126 fmol/well 
vs. 282±41 fmol/well), while treatment with hydralazine did not significantly affect mRNA 
expression and activity of sGC (alpha1 116±15%, beta1 118±17% and NO-stimulated 
cGMP levels 206±37 fmol/well). 
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Figure 27: Effects of Bay 41-2272 (+Bay 41-2272) and hydralazine (+Hydralazine) 
on tubulointerstitial sGC mRNA expression and activity to produce cGMP 16 weeks 
after induction of chronic-progressive anti-thy1 glomerulosclerosis (cGS). Treatments 
were started 7 days after injection of anti-thy1 antibody into uni-nephrectomized rats. 
Non-diseased animals without (2-K Control) or with uni-nephrectomy (1-K Control) 
received a PBS injection. mRNA was analyzed by a real-time PCR method using 
GAPDH as housekeeping gene. mRNA is shown as a percentage of the untreated 
chronic anti-thy1 animals. cGMP generation was measured by ELISA in cortical tissue 
from individual animals in the presence or absence of the NO donor DEA/NO. (**p<0.01 
vs. cGS+Hydralazine, *p<0.05 vs. Control, #p<0.05 vs. cGS) 
3.4.8 Glomerular sGC activity 
As shown in Figure 28, glomerular cGMP production was evaluated as sGC activity. 
In comparison to the normal control animals, basal and NO-stimulated glomerular 
cGMP production was lower in the untreated chronic anti-thy1 animals (-40%, P>0.05 
and -58%, p<0.05 vs. 2-K Control 15±1 fmol/well and 77±7 fmol/well, respectively). 
Treatment with Bay 41-2272 increased basal (12±2 fmol/well vs. cGS: 9±1 fmol/well, 
p=0.17) and NO-stimulated cGMP production (59±8 fmol/well vs. cGS: 32±4 fmol/well, 
p<0.01), as compared to the untreated chronic anti-thy1 group, while hydralazine 
administration did not affect basal and NO-stimulated glomerular cGMP synthesis 
(8.64±1.45 fmol/well and 29±4 fmol/well, respectively). 
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Figure 28: Effects of Bay 41-2272 (+Bay 41-2272) and hydralazine (+Hydralazine) 
on glomerular sGC activity to produce cGMP 16 weeks after induction of chronic-
progressive anti-thy1 glomerulosclerosis (cGS). Treatments were started 7 days after 
injection of anti-thy1 antibody into uni-nephrectomized rats. Non-diseased animals 
without (2-K Control) or with uni-nephrectomy (1-K Control) received a PBS injection. 
cGMP generation was measured by ELISA in glomeruli harvested from individual 
animals in the presence or absence of the NO donor DEA/NO. (**p<0.01 and ##p<0.01 
vs. cGS and cGS+Hydralazine) 
3.4.9 Renal macrophage infiltration 
As shown in Figure 29, the diseased groups had more cortical and glomerular 
macrophage infiltration than the 2-K (9.17±0.4 and 0.7±0.14 ED1-positive cells/section) 
and 1-K (7.86±1.25 and 0.7±0.21 ED1-positive cells/section) Control groups. Cortical 
and glomerular macrophage infiltration were significantly inhibited by Bay 41-2272 
treatment (-39.7% and -46.7%), in contrast to cGS (58±5 and 2.55±0.33 ED1-positive 
cells/section), while hydralazine treatment did not affect macrophage infiltration (51±5 
and 2.58±0.32 ED1-positive cells/section). 
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Figure 29: Effects of Bay 41-2272 (+Bay 41-2272) and hydralazine (+Hydralazine) 
on cortical and glomerular ED1-positive cells infiltration 16 weeks after induction of 
chronic-progressive anti-thy1 glomerulosclerosis (cGS). Treatments were started 7 
days after injection of anti-thy1 antibody into uni-nephrectomized rats. Non-diseased 
animals without (2-K Control) or with uni-nephrectomy (1-K Control) received a PBS 
injection. Data are expressed as ED1-positive cells per cortical section observed at 
x200 magnification and per glomerular cross-section. (**p<0.01 vs. cGS, ##p<0.01 and 
#p<0.05 vs. cGS+Hydralazine) 
 
As shown in Figure 30, and as it is consistent with macrophage infiltration, the 
untreated cGS group (100±15%) had significantly more tubulointerstitial P-selectin 
mRNA expression, which is important for macrophage infiltration, than the 2-K (8±1%) 
and 1-K (13±2%) Control groups. Bay 41-2272 administration inhibited tubulointerstitial 
P-selectin mRNA expression significantly (-47%) as compared to cGS, while 
hydralazine only slightly lowered P-selectin mRNA expression (-19%). 
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Figure 30: Effects of Bay 41-2272 (+Bay 41-2272) and hydralazine (+Hydralazine) 
on tubulointerstitial P-selectin mRNA expression 16 weeks after induction of chronic-
progressive anti-thy1 glomerulosclerosis (cGS). Treatments were started 7 days after 
injection of anti-thy1 antibody into uni-nephrectomized rats. Non-diseased animals 
without (2-K Control) or with uni-nephrectomy (1-K Control) received a PBS injection. 
mRNA was analyzed by a real-time PCR method using GAPDH as housekeeping gene. 
mRNA is shown as a percentage of the untreated chronic anti-thy1 animals. (*p<0.05 vs. 
cGS) 
 
To sum up, in chronic progressive anti-thy1-induced glomerulosclerosis, 
tubulointerstitial sGC activity was significantly up-regulated, whereas glomerular sGC 
activity was diminished. Bay 41-2272 supplementation markedly increased both 
tubulointerstitial and glomerular sGC activity and subsequently slowed the progression 
of tubulointerstitial sclerosis and glomerulosclerosis in a blood pressure-independent 
manner. 
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4 Discussion  
The aim of this study was to analyze the relation between the NO-cGMP cascade 
and the time course of renal fibrosis from injury to progressive matrix expansion. The 
results of the study show that the activity and expression of the NO-cGMP pathway are 
transcriptionally regulated during the injury, matrix expansion and progression phases 
in the rat model. Specific stimulation of NO-sGC signaling by Bay 41-2272 limits TGF-
beta overexpression and matrix expansion, although it demonstrates no effects on 
mesangial cell lysis due to lack of the effector receptor sGC, suggesting its 
therapeutical differentiation between the beneficial and detrimental actions of the L-
arginine-NO pathway. Before the results obtained will be discussed in detail, I would 
like to first evaluate the methodology used. 
4.1 Critical evaluation of the methodology used 
4.1.1 Animal model of anti-thy1-induced acute and chronic renal disease 
A single injection of anti-thy1 antibody into normal or uni-nephrectomized rats 
causes a sequence of distinct phases of “injury”, “matrix expansion” and subsequent 
“progression”, which enable us to study the NO-cGMP pathway in different processes 
separately, while most renal disease models show no distinct injury phase and involve 
overlapping cycles of tissue injury and matrix expansion, such as the model of 
hypertension and diabetes. The injury phase is characterized by marked inducible NO 
production and mesangial cell lysis, which has also been found in IgA nephropathy, 
Wegener’s granulomatosis, lupus nephritis, acute tubular necrosis and kidney 
transplant rejection. The subsequent fibrosis is characterized by matrix protein 
accumulation, which is similar to human mesangioproliferative glomerulonephritis and 
IgA nephropathy. All these histological features can be found in many experimental and 
human renal diseases [65]. Hence the model was chosen to interpret the relevant role 
of the NO-cGMP pathway and its modification in human renal disease. Renal mesangial 
cells are specialized smooth muscle cells that play an important role in the structural 
support of the glomerulus and in the control of glomerular filtration rate [66]. In the same 
way as shown in our model, they contribute also to the pathological processes of the 
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glomerulus, particularly in glomerulonephritis and glomerulosclerosis. The NO-cGMP 
pathway plays an important role in mesangial cells [31], which might indicate an 
important role of NO-cGMP signal transduction in kidney diseases, such as mesangial 
proliferative glomerulonephritis. Therefore, we tested the hypothesis in anti-thy1 
glomerulonephritis, an animal model for mesangial proliferative glomerulonephritis, 
which is ideal for studying the NO-cGMP pathway in vivo in comparison to the in vitro 
studies on the mesangial cell. 
The common final pathway of chronic renal disease, independent of the primary 
disorder, suggests that a self-progressing mechanism and a common intrarenally 
determined program are operating, since the ongoing deterioration of organ function 
occurs even if the initial disease has been removed [9]. In the present study, anti-thy1-
induced chronic glomerulosclerosis was produced through an injection of anti-thy1 
antibody and a persistent hyperfiltration injury of the remaining kidney, which is 
consistent with a self-perpetuating and intrarenal common final pathway in many 
chronic renal diseases, while the ongoing and extrarenal injuries obliterate the decrease 
in renal function in the diabetic and hypertensive nephropathy models. Therefore, anti-
thy1-induced glomerulosclerosis provides a good in vivo method to characterize the 
intrarenally self-progressing pathway contributing to chronic renal fibrosis. Because the 
molecular mechanisms of matrix expansion in various renal diseases, such as diabetic 
and hypertensive nephropathy, are rather common, the findings of this study may be 
relevant for fibrotic renal disease in general. 
4.1.2 Analysis of markers of renal fibrosis 
In the anti-thy1 glomerulonephritis animal model, the progressive renal disease is 
glomerular in origin. Thus, the measurements of sclerotic parameters in glomeruli are 
very important for this research. However, glomeruli occupy only 3-4% of the kidney 
volume compared to the >90% comprised by tubules and the interstitium [67]. 
Therefore, the metal sieves technique was used to yield glomeruli. Many studies have 
shown that tubulointerstitial injury and fibrosis correlate best with renal disease 
progression and insufficiency and develop independently no matter whether they 
originate from primarily glomerular or vascular lesions [68]. In anti-thy1-induced chronic 
glomerulosclerosis, the TGF-beta overexpression and matrix expansion spread from 
                                                                                                                           4 Discussion 
 - 73 - 
the glomeruli into the tubulointerstitium. Thus, the parameters of tubulointerstitial 
fibrosis are very important in the evaluation of chronic progression. Since renal cortex 
consists mainly of tubulointerstitial tissue (>95%), it was used as representative of the 
tubulointerstitium. The separation of glomeruli and cortical cell enables us to study the 
fibrogenic responses of the glomeruli and the tubulointerstitium of every individual 
animal separately, including the production of TGF-beta, fibronectin and PAI-1 at 
protein level in cell culture and at mRNA level.  
There were preliminary studies in our work group, which showed that the production 
of TGF-beta1, fibronectin and PAI-1 by isolated glomeruli and cortical cells is constant 
for 48 hours in culture. The 48-hour harvesting of culture supernatant was chosen on 
the basis of these data and the fact that the quantities of these molecules are sufficient 
to get accurate ELISA measurements and correlate to ECM accumulation in vivo [69]. 
As shown in the results, there is a big difference in disease parameters, such as 
glomerular and cortical TGF-beta1, fibronectin and PAI-1 expression, between 
untreated diseased rats and normal controls, and these differences enable detection of 
small differences in therapeutic efficacy. ELISA data obtained from individual rats 
presented the fibrotic severity precisely, in contrast to quantization from PAS staining, 
which is variable in tissue sectioning, staining intensity and subjective scores. 
4.1.3 TGF-beta1 as a key marker of matrix expansion 
Determination of the key fibrosis mediator TGF-beta1 is a valid sensitive marker of 
renal matrix expansion [56, 70]. This concept is proved in the rat model of anti-thy1 
glomerulonephritis. In animals with two kidneys, anti-thy1 antibody injection leads to 
acute and reversible mesangioproliferative glomerulonephritis, in which TGF-beta 
returns to normal after the resolution of mesangial cell injury; whereas in uni-
nephrectomized rats, injection of anti-thy1 antibody results in persisting TGF-beta 
overexpression and progressive glomerulosclerosis and tubulointerstitial fibrosis. The 
analysis of PAI-1 and fibronectin levels can also be an important evaluation of the anti-
fibrotic effect of a new therapy independent of TGF-beta, by reflecting the imbalance of 
ECM synthesis and degradation. In this study, it is shown that TGF-beta production had 
a close relation with fibronectin and PAI-1 production and ECM accumulation, indicating 
that the increase in matrix accumulation is likely to result from both elevated matrix 
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synthesis and inhibited matrix degradation.  
4.1.4 Stimulation of sGC by Bay 41-2272 
Due to the importance of NO-cGMP signal transduction, modulation of this signaling 
cascade has attracted much attention. L-arginine and NO donor administration have 
long been used to modulate the NO-cGMP pathway. However, experimental studies 
have shown both therapeutic and detrimental consequences of treatment with L-
arginine and NO donor, since the effector molecular effects of NO have also contributed 
to it. The use of L-arginine is not only obstructed by the potential synthesis of cytotoxic 
amounts of NO via iNOS, but also by the generation of agmatine, proline and 
polyamines via alternative L-arginine-metabolizing pathways, which are involved in 
renal tissue repair through different, partly opposing mechanisms [5]. The use of 
pharmacological NO donors leads to a rather unspecific release of NO across the whole 
body, is prone to tachyphylaxis and has been linked to an unwanted pro-oxidant activity 
[71]. In contrast, the new class of sGC modulators, such as Bay 41-2272, has attracted 
particular interest as the target of the L-arginine-NO-cGMP signal transduction without 
the formation of by-products, NO oxidative effects and tolerance, since they amplify the 
cGMP levels exactly at the downstream effector of NO, where cGMP is naturally 
generated. Therefore, sGC stimulators represent useful pharmacological tools to 
differentiate between signal molecular and effector molecular effects of NO. 
In order to further define the role of the NO-cGMP pathway in renal disease, the rat 
model with anti-thy1 glomerulonephritis was first used to study the in vivo effects of Bay 
41-2272 on renal function, pathology and the expression of pro-inflammatory and pro-
fibrogenic factors. Second, in vitro cultures of glomeruli were used to study the possible 
mechanisms for the renoprotective effect of Bay 41-2272. Finally, the effects of Bay 41-
2272 on the renal disease progression in this rat model were compared with those of a 
vasodilator, hydralazine.  
4.2 The NO-cGMP pathway in the injury phase of acute anti-thy1 
glomerulonephritis 
The predominant mechanism of the injury phase is mesangial cell lysis, which is 
dependent on the generation of cytotoxic NO through iNOS. The sustained and high-
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output generation of NO by iNOS may result in a broad spectrum of consequences, 
such as lipid peroxidation, DNA damage and pro-apoptotic effects. In this protocol, we 
observed the regulation of glomerular NO-cGMP signal transduction, its relation to 
inducible NO production and mesangial cell lysis and the effects of pretreatment with 
Bay 41-2272 on the injury phase. 
4.2.1 Regulation of NO-cGMP signal transduction 
It was interesting to find that there was about 90% decrease in glomerular alpha1 
sGC and beta1 sGC expression of nephritic rats shortly after anti-thy1 antibody-induced 
mesangial cell injury had occurred. Corresponding to the gene expression, nephritic 
rats had significantly lower basal glomerular cGMP, which additionally could hardly be 
stimulated by DEA/NO. Bay 41-2272 pretreatment failed to stimulate sGC expression 
and activity to exogenous NO stimulation, probably because of the loss of glomerular 
sGC. The disruption of the NO-cGMP cascade paralleled the mesangial cell lysis, 
consistent with a high degree of sGC distribution in mesangial cells [31]. It has been 
reported that pro-inflammatory cytokines, such as interleukin-1beta and TNF-alpha, 
decrease the half-life of the sGC subunit [72]. Prolonged incubation of smooth muscle 
cells with NO donors has been shown to decrease sGC activity, protein and mRNA [73]. 
This suggests that high-output NO derived from iNOS and cytokines may also modulate 
sGC subunit expression. In contrast to the traditional meaning of “NO deficiency”, 
resulting from reduction in L-arginine and eNOS, decreased cGMP was present in the 
injury model with high-output NO production and normal eNOS expression. These 
results have opened a new explanation for “NO deficiency”. 
4.2.2 Effects of Bay 41-2272 on mesangial cell lysis 
In rat nephrotoxic nephritis, macrophage infiltration was decreased by iNOS 
inhibition, accompanied by an increase in eNOS [74]. It has been shown that in human 
mesangial cells, iNOS mRNA half-life was reduced by the NO-cGMP pathway to 
regulate the toxic effects of high levels of NO [66]. Then I inquired if Bay 41-2272 might 
activate the L-arginine-eNOS-cGMP pathway to depress the L-arginine-iNOS-NO 
pathway in the injury phase. As shown in the results, the animals in protocol 1 displayed 
a typical manifestation of the injury phase in acute anti-thy1 glomerulonephritis: up-
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regulation of iNOS mRNA expression with a high-output of NO and mesangial cell lysis. 
Pretreatment with Bay 41-2272 could not increase cGMP synthesis, perhaps due to the 
lack of the receptor sGC. With this in mind, it is not surprising that Bay 41-2272 had no 
effect on the degree of anti-thy1-induced mesangial cell injury, including proteinuria, 
mesangial cell counts, and NO output and iNOS mRNA expression. But it should be 
emphasized that unlike L-Arginine, which can increase mesangial cell injury due to pro-
fibrogenic by-products and increased oxidative stress, Bay 41-2272 has no negative 
effects on the injury phase. It even slightly decreased proteinuria in our study. Hence, 
the deficiency of target receptor sGC in the injury phase is the reason for the lack of 
Bay 41-2272 effects in this phase of the disease. 
4.3 The NO-cGMP pathway in the matrix expansion phase of acute anti-thy1 
glomerulonephritis 
In the matrix expansion phase following the injury phase, overexpression of TGF-
beta and accumulation of ECM are the main features. In this protocol, we observed the 
alteration of the glomerular NO-cGMP signal transduction, its relation to glomerular 
TGF-beta1 overexpression and matrix accumulation and the effects of an administration 
of Bay 41-2272 on glomerular matrix expansion.  
4.3.1 Regulation of NO-cGMP signal transduction 
In contrast to the injury phase, a dramatic change of sGC was shown in the matrix 
expansion phase. Alpha1 sGC and beta1 sGC expression increased 5.6-fold and 3.3-
fold in untreated nephritic rats. Although already up-regulated by the disease itself, Bay 
41-2272 treatment further elevated the expression of alpha1 sGC and beta1 sGC 17.6-
fold and 12.2-fold. The increase in sGC expression in the nephritic group is parallel to 
mesangial cell proliferation, indicating that sGC expresses significantly in mesangial 
cells, which is consistent with the disruption of sGC expression in the injury phase 
accompanied by mesangiolysis. Apart from increasing sGC expression, sGC activity to 
generate cGMP was also increased by the disease itself and significantly further 
amplified by Bay 41-2272, which is parallel to sGC mRNA expression. Of interest in this 
context is the finding that sGC enhancer treatment not only significantly increased 
glomerular NO-induced cGMP generation, but also the mRNA expression of both 
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subunits of the sGC. This may represent a self-reinforcement mechanism through 
which Bay 41-2272 can influence the expression of its effectors. However, it might as 
well be just a consequence of the improved glomerular wound repair in the treatment 
group. The increased sGC expression by Bay 41-2272 treatment, on the other hand, is 
a novel observation that has not been previously reported. It becomes important in 
pathophysiologic conditions, where deficient sGC expression is characterized. However, 
this is in contrast to the data from many cardiovascular studies, which have shown 
decreases in sGC expression and activity in hypertensive animal models [75, 76]. This 
may represent divergent regulatory mechanisms in the two different organs. In acute 
anti-thy1 glomerulonephritis, glomerular sGC expression and activity are 
compensatorily increased and relatively impaired, which may not suffice to counteract 
the fibrotic response, whereas Bay 41-2272 further elevated sGC expression and 
cGMP levels to limit matrix expansion. In addition, similar to the results in the injury 
phase, eNOS expression did not decrease in nephritic animals, which is consistent with 
no decrease in renal eNOS expression found in hypertensive rats [53], suggesting no 
eNOS-NO deficiency in the matrix expansion phase of acute anti-thy1 
glomerulonephritis. Moreover, Bay 41-2272 increased eNOS expression 
transcriptionally. Further studies will be done to explore the mechanism of the up-
regulation of eNOS expression by Bay 41-2272. 
4.3.2 Antifibrotic effects of Bay 41-2272 
In the present study, increases in glomerular production of 10.5-fold for TGF-beta1, 
9-fold for fibronectin and 3.4-fold for PAI-1 were seen in the untreated nephritic group 
when compared to normal controls. These significant differences make it possible to 
observe the antifibrotic effects of Bay 41-2272. The cGMP levels further amplified by 
Bay 41-2272 significantly limited the fibrotic response of the matrix expansion phase, as 
shown by reductions in proteinuria, glomerular histological matrix accumulation and 
expression of TGF-beta1, fibronectin and PAI-1. Although all disease parameters prove 
the antifibrotic effects of Bay 41-2272, it remains unclear how enhanced NO-cGMP 
signal transduction results in the decrease in TGF-beta1 overexpression and the 
antifibrotic effect, which will be discussed later. It has been previously proved that L-
arginine has antifibrotic action in anti-thy1 glomerulonephritis mediated by endogenous 
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production of NO through limiting TGF-beta overexpression [16]. Our findings further 
prove that the antifibrotic action of NO in renal fibrosis is mediated by cGMP through 
sGC modification.  
4.4 The NO-cGMP pathway in anti-thy1-induced chronic glomerulosclerosis 
In this study, increased blood urea and creatinine associated with marked reduction 
in the glomerular filtration rate and hematocrit were observed in anti-thy1-induced 
chronic glomerulosclerosis, indicating impaired renal function. In this protocol, we 
observed the change of the tubulointerstitial and glomerular NO-cGMP signal 
transduction in the progression phase of chronic anti-thy1-induced glomerulosclerosis 
16 weeks after antibody injection, its correlation with glomerulosclerosis, 
tubulointerstitial fibrosis and renal insufficiency and the effects of the sGC enhancement 
by Bay 41-2272 on slowing the progressive course of chronic anti-thy1-induced 
glomerulosclerosis. In addition, the sole vasodilator hydralazine was used to investigate 
the blood pressure-independent effect of Bay 41-2272. 
4.4.1 Regulation of NO-cGMP signal transduction 
Very little is known about the long-term regulation of sGC in the kidney. sGC 
expression and activity showed contrary change in the glomeruli and the 
tubulointerstitium of the chronic model. In parallel to increased glomerular expression 
and activity of sGC in acute anti-thy1 glomerulonephritis, tubulointerstitial sGC mRNA 
expression and NO-dependent cGMP production were significantly up-regulated in the 
presence of marked tubulointerstitial fibrosis 16 weeks after induction of progressive 
anti-thy1 glomerulosclerosis. However, glomerular sGC expression and activity were 
significantly inhibited, in contrast to tubulointerstitial NO-cGMP signaling in the same 
model at the same time, but also to the strong up-regulated glomerular sGC activity in 
the matrix expansion phase of the acute model. Although Bay 41-2272 could not 
enhance sGC expression, sGC activity in response to NO stimulation in both depressed 
glomerular and elevated tubulointerstitial sGC expression was significantly enhanced by 
Bay 41-2272 treatment. Therefore, subsensitivity of sGC to NO stimulation, as 
observed in our results, could attenuate the efficacy of NO-cGMP signal transduction, 
contributing to the progression of renal disease. Compared to the relatively impaired 
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tubulointerstitial sGC, the glomerular sGC was completely impaired. The up-regulation 
of tubulointerstitial sGC expression in diseased rats might also be a self-compensatory 
effect to counteract the renal fibrosis.  
Endothelium-independent NO-cGMP signaling by exogenous NO donor was blunted, 
indicating that dysfunction of sGC may be responsible for the blunted endothelium-
independent NO-cGMP pathway. Considering slightly increased eNOS mRNA in 
diseased rats in the study, these alterations in the NO-cGMP system, namely, the 
enhanced eNOS-NO pathway and impaired sGC-cGMP pathway, seem to be the 
phenotypic character of renal fibrosis rats. Dysfunction of sGC-cGMP rather than 
eNOS-NO deficiency contributes to the impairment of NO-cGMP signal transduction in 
our animal model. 
4.4.2 Antifibrotic effects of Bay 41-2272 
Bay 41-2272 treatment increased cGMP generation and subsequently markedly 
limited the glomerular and tubulointerstitial progression in this model, as shown by 
reduced histological glomerular and tubulointerstitial fibrosis and expression of TGF-
beta1, fibronectin and PAI-1. The inhibitory effects on TGF-beta1, fibronectin and PAI-1 
protein and mRNA expression lead to a decrease in ECM synthesis and an increase in 
ECM protein degradation resulting in limiting renal fibrosis. In addition, administration of 
the sGC stimulator lowered blood creatinine and urea concentrations and increased 
creatinine clearance and hematocrit levels, underscoring that the morphological and 
molecular glomerular and tubulointerstitial benefits achieved went along with improved 
renal function. The present study in progressive anti-thy1-induced chronic 
glomerulosclerosis confirms the critical role of sGC and NO-dependent cGMP 
production in pathological renal matrix accumulation revealed in the acute anti-thy1 
model. The important role of sGC in fibrotic kidney disease is thereby now expanded 
from glomerular to tubulointerstitial TGF-beta overexpression and matrix expansion, as 
well as from acute, reversible to chronic progressive renal disease.  
However, at the glomerular level, Bay 41-2272 reduced TGF-beta1, fibronectin and 
PAI-1 as well, but the benefits are more moderate than those at the tubulointerstitial 
level. In addition, Bay 41-2272 treatment has no statistically significant effect on 
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proteinuria, which mainly reflects glomerular barrier impairment. It seems that Bay 41-
2272 could reduce tubulointerstitial impairment more effectively than glomerular 
impairment. I think the possible reason is that Bay 41-2272 treatment was started as 
late as 7 days after induction of anti-thy1 glomerulosclerosis; at this point in time, the 
glomerular disease was already established. This view is supported by the results in the 
matrix expansion phase of acute anti-thy1 glomerulonephritis, in which Bay 41-2272 
has significant effects on reducing glomerular TGF-beta1 overexpression, fibronectin, 
PAI-1 and proteinuria when begun as early as 24 hours after anti-thy1 
glomerulonephritis induction. On the other hand, a late start of the therapy may result in 
more serious sGC impairment in the glomeruli than in the tubulointerstitium, which also 
leads to a less efficiency of Bay 41-2272 on proteinuria. In addition, it has been pointed 
out that proteinuria in anti-thy1-induced renal disease does not always follow the 
severity of the fibrotic response [77]. Thus, the finding that proteinuria is not significantly 
reduced in the chronic model is of interest, yet the reasons for it remain unclear. 
4.5 Transcriptional regulation of NO-cGMP signal transduction from acute to 
chronic renal disease 
As shown in the model of anti-thy1-induced renal disease, the NO-cGMP pathway 
displayed interesting changes from initial injury to the following matrix expansion phase 
and the final progressive fibrosis. It opened a new understanding of the pathogenesis of 
renal fibrosis. Previously, it had generally been assumed that the activity of this 
pathway is mainly dependent on the capability of eNOS to generate NO [3, 4, 5]. In this 
sense, impaired renal NO production has been linked to an insufficient supply with its 
main precursor L-arginine and the co-factor tetrahydrobiopterin as well as to increased 
deactivation of the NO produced, for example, by free radicals [5, 6, 78]. Therefore, the 
term NO deficiency has been mainly understood as deficiency in the synthesis of NO, 
and sGC has played a rather passive role. The sGC enzyme has been thought to be 
expressed constitutively and to transduce the NO signal without further modulation [79]. 
However, these findings in acute and chronic anti-thy1-induced renal diseases reveal 
that sGC can be the object of a marked transcriptional regulation as well and this 
relates directly to the subsequent ability of NO to produce cGMP. 
In this study, there is no eNOS down-regulation in the acute and chronic 
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glomerulonephritis models, suggesting that NO deficiency from eNOS does not play a 
key role in the renal matrix expansion of our model. However, the dramatic down- and 
up-regulation of sGC expression and activity was found in this model. Hence, the 
impaired sGC activity may be the main reason for ‘NO deficiency’ in observed renal 
disease and NO-cGMP signal transduction impairment, indicating an impairment of NO-
dependent signaling transduction either at the level of or downstream from sGC. This 
finding is evident in the injury phase. Despite glomerular NO production being markedly 
increased, the glomerular NO-cGMP pathway was disrupted due to the loss of the sGC 
enzyme. Similarly, a decrease in the expression or activity of vascular sGC has recently 
been reported in several disease models characterized by a functional NO deficiency, 
including spontaneously hypertensive rats, aging, myocardial infarction, angiotensin II 
infusion, lead-induced hypertension and diabetic Goto-Kakizata rats [53, 75, 80, 81, 82, 
83]. In many of these studies, endothelial NO production was found to be normal or 
even increased as well. Thus, due to the uncoupling of the eNOS-NO and sGC-cGMP 
pathway, impaired expression or activity of sGC can functionally mimic “NO deficiency”. 
In acute anti-thy1 glomerulonephritis, glomerular sGC-cGMP signaling experienced 
dramatic and contrary alterations, from almost totally disrupted to markedly up-
regulated expression and activity, consistent with the pathological change from 
mesangiolysis to mesangial cell proliferation and glomerular matrix expansion. Thus, it 
may be speculated that the change in glomerular sGC is related to the amount of its 
main host cells, mesangial cells, during the course of acute anti-thy1 glomerulonephritis. 
In progressive anti-thy1-induced chronic glomerulosclerosis, both glomerular and 
tubulointerstitial fibrosis contribute to the deterioration of renal function. Interestingly, it 
was found that the NO-cGMP pathway in the glomeruli was not consistent with the one 
in the tubulointerstitial tissue. Tubulointerstitial sGC activity after NO stimulation was 
markedly up-regulated, while the sGC activity of glomeruli was completely impaired. 
Compared to the glomeruli in the matrix expansion phase of acute anti-thy1 
glomerulonephritis, glomerular cGMP production in response to NO was about 1187-
fold down-regulated 16 weeks after disease induction, and tubulointerstitial cGMP 
synthesis stimulated by NO was 135-fold depressed. That is to say, the severity of the 
NO-sGC-cGMP impairment was in an ascending sequence: glomeruli in acute 
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glomerulonephritis, tubulointerstitium in chronic glomerulosclerosis and glomeruli in 
chronic glomerulosclerosis, which is consistent with the time course of chronic renal 
disease, from acute to chronic, with ongoing TGF-beta overexpression, from the 
glomerular compartment to the interstitial compartment, and from relative impairment to 
absolute insufficiency.  
Because of the long period of disease in the chronic model, the mechanisms 
involved in the impairment of NO-cGMP are more complicated than those in the acute 
model. Several reasons are reported for the dysfunction of sGC in the kidney, such as a 
reduction in the enzyme’s heme content and/or oxidation of the heme iron [83] and a 
mutation of prosthetic heme in sGC [84]. Metabolic changes, such as 
hypercholesterolemia, chronic hypertension, aging, oxidative factor and morphologic 
changes may contribute to the impairment of signaling downstream from NO, sGC 
expression or activity [75, 85, 86]. In this study, compared to old hypertensive chronic 
diseased rats, the glomerular sGC activity in response to NO stimulation of young 
normotensive acute nephritic rats was 1187-fold higher. All these reasons may be 
attributed to the subsensitivity of sGC cooperatively. The up-regulated sGC activity in 
the glomeruli of the acute model and the tubulointerstitium of the chronic model may 
reflect a self-compensatory mechanism for holding the disease progression. However, 
compensatorily increased cGMP levels cannot counteract the pathogenetic factors, 
otherwise fibrogenic factors could inhibit sGC compensation, resulting in relative 
insufficiency. But Bay 41-2272 treatment could go on stimulating sGC activity to 
improve renal disease. The impairment of the sGC-cGMP pathway could represent a 
mechanism by which pro-fibrotic agents reduce activation of the antifibrotic pathway. 
4.6 Mechanisms of Bay 41-2272’s antifibrotic effects 
In order to further characterize the role of the NO-cGMP pathway in anti-thy1-
induced renal disease, the specific sGC stimulator was used in this study. It showed 
that Bay 41-2272 ameliorates renal fibrosis via further increases in cGMP levels, 
resulting in the restoration of renal function in anti-thy1 glomerulonephritis, indicating a 
potential pharmacological target for the treatment of progressive renal fibrosis. There 
are several mechanisms that may be involved in antifibrotic effects via the increased 
cGMP. 
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4.6.1 Reduction in blood pressure 
Systemic hypertension is a major risk factor that determines the rate of progression 
of renal disease [87, 88]. Transmission of the systemic blood pressure to the 
glomerulus may induce an adaptive glomerular hyperfiltration and an increase in 
glomerular capillary pressure leading to consequent glomerular hypertrophy and 
sclerosis [89, 90]. In addition, chronic hypertension may result in vascular narrowing, 
causing glomerular hypoperfusion and ischemic nephropathy [91]. This risk factor plays 
a more important role in anti-thy1 chronic glomerulosclerosis than in acute anti-thy1 
glomerulonephritis, since the rats with anti-thy1-induced chronic glomerulosclerosis 
showed significantly high blood pressure, in contrast to the rats of acute anti-thy1 
glomerulonephritis with normal blood pressure. Bay 41-2272 treatment reduced the 
systolic blood pressure of animals in the acute and the chronic models. Several 
mechanisms to decrease blood pressure via cGMP have been discussed in the 
literature. Activation of sGC in the vascular smooth muscle cell increases the 
conversion of GTP to cGMP, which regulates the intracellular Ca2+ and inhibits 
vasoconstricting factors, such as endothelin-1, and then decreases the blood pressure 
[48]. Therefore, sGC is an important target protein for regulating blood pressure. Due to 
the wide distribution of sGC in mesangial cells and vascular smooth muscle cells of the 
kidney, it is not surprising that Bay 41-2272 can reduce the glomerular hyperfiltration 
and hyperperfusion to prevent these hemodynamic adaptations as well as the 
subsequent complications via beneficial effects on systemic and intraglomerular blood 
pressure. Considering that renal vasoconstriction may contribute to the progression of 
chronic renal diseases, improved renal function could be explained by an effect of Bay 
41-2272 upon renal circulation. 
4.6.2 Blood pressure-independent effects of Bay 41-2272 
Bay 41-2272 can significantly decrease systolic blood pressure by increasing cGMP, 
which leads to the question if the antifibrotic action of Bay 41-2272 is mediated by 
reduced glomerular blood pressure. However, there was a Bay 41-2272 dose-
dependent reduction in TGF-beta1 protein synthesis in cultured normal and nephritic 
glomeruli, an environment where blood pressure plays no role. In addition, acute anti-
thy1 glomerulonephritis is a normotensive model, and it has been found that systemic 
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hypertension and treatment with high doses of ß-blocker does not influence the excess 
of the mesangial matrix deposition in this model [92], and renovascular hypertension did 
not influence healing of the glomerular lesions in the acute anti-thymocyte serum 
nephritis [93]. These findings suggest that sGC stimulation to increase cGMP can inhibit 
TGF-beta1 expression via a direct and blood pressure-independent mechanism in the 
model with acute glomerulonephritis.  
In the chronic glomerulosclerosis model, the sole vasodilator hydralazine did not 
significantly alter the degrees of glomerulosclerosis, tubulointerstitial fibrosis and renal 
insufficiency, despite a comparable blood pressure decrease having been achieved, 
while only Bay 41-2272 significantly reduced pro-fibrotic factors, such as TGF-beta1, 
fibronectin and PAI-1, inflammatory cell infiltration and histological signs of 
glomerulosclerosis. This suggests that Bay 41-2272 slowed the progressive course of 
anti-thy1-induced glomerulosclerosis and appeared to be at least in part independent of 
blood pressure reduction. Renal TGF-beta1 overexpression and matrix accumulation 
were also reduced by blood pressure-independent mechanisms. The superiority of Bay 
41-2272 over conventional antihypertensive therapies may result from elevated cGMP 
levels. Therefore, enhancement of cGMP production probably has antifibrotic effects 
that are independent of the reduction in blood pressure, which includes the following 
three mechanisms. 
4.6.2.1 Direct reduction in TGF-beta1 expression 
The renal pathology of anti-thy1 glomerulonephritis is characterized by ongoing 
TGF-beta1 overexpression, progressive glomerulosclerosis and interstitial fibrosis. 
These pathological changes were ameliorated by Bay 41-2272. A variety of mediators, 
including TGF-beta1, fibronectin and PAI-1, which are important growth factors for ECM 
production, were down-regulated by elevated cGMP. Therefore, one of the possible 
mechanisms for renoprotection may be linked to the direct effect of cGMP against pro-
fibrotic factors and the subsequent inhibition of matrix protein deposition in the kidney. 
4.6.2.2 Inhibition of renal platelet deposition 
Platelet aggregation is important for the progression of glomerulonephritis through 
release of fibrogenic growth factors such as TGF-beta and platelet-derived growth 
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factor and can participate in the synthesis of the mesangial matrix [94]. It is assumed 
that the effects of NO on modulating platelet reactivity are mediated via the activation of 
sGC, the formation of cGMP and the subsequent activation of PKG, which can 
phosphorylate several proteins to decrease the intraplatelet free calcium levels and 
inhibit platelet activation and aggregation [95]. It has been shown that platelet inhibition 
via clopidogrel limited TGF-beta overexpression and matrix accumulation in the matrix 
expansion phase of acute anti-thy1 glomerulonephritis [58]. Bay 41-2272 
supplementation increased plasma cGMP levels, prolonged the bleeding time and 
decreased glomerular fibrinogen deposition, indicating a reduction of platelet 
aggregation and glomerular platelet deposition via sGC-cGMP pathway stimulation, 
which correlated with reduced proteinuria, pro-fibrotic factors and renal fibrosis. Hence, 
inhibiting the pathological platelet activation may be another mechanism to slow down 
the progression of renal diseases. 
4.6.2.3 Inhibition of renal macrophage infiltration 
In the injury phase, macrophages produce NO, reactive oxygen species and 
proteases mediating mesangiolysis [14]. Later, macrophages can release cytokines and 
growth factors including TGF-beta which are important stimuli to the production of ECM 
[14]. During glomerular inflammation, cytokines and chemokines synthesized by 
mesangial cells modulate the expression of adhesion molecules involved in the 
infiltration, activation and differentiation of inflammatory cells within the glomeruli [96]. In 
the present study, infiltrating glomerular and interstitial macrophages, ED1-positive cells, 
were reduced by Bay 41-2272 treatment. Furthermore, P-selectin, an important 
adhesion molecule for leukocyte recruitment, was down-regulated by Bay 41-2272, 
indicating that the mechanism of Bay 41-2272 in reducing inflammation is due to 
inhibition of macrophage adhesion through an increase in cGMP content. This is 
consistent with a recent study, in which Bay 41-2272 and NO donor could stimulate the 
NO-cGMP pathway to inhibit P-selectin expression, leukocyte recruitment and 
inflammation in postcapillary venules [97]. In addition, Bay 41-2272 has vasodilatory 
properties and inhibits platelet aggregation to prevent adherence of leucocytes and 
platelets to the endothelium. They can result in the reduction of renal inflammation and 
renal fibrosis. This implies that elevated cGMP levels through Bay 41-2272, a sGC 
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stimulator, can directly reduce macrophage infiltration and adhesion molecule 
expression to slow the progression of anti-thy1-induced renal disease. 
Specific stimulation of sGC signaling by Bay 41-2272 significantly limits pathological 
matrix expansion in the kidney and the course of progressive renal disease at least 
partially in a manner independent of blood pressure via direct inhibition of renal TGF-
beta1 overexpression, platelet deposition and macrophage infiltration. 
4.7 To differentiate the beneficial and detrimental actions of the L-arginine-NO 
pathway 
Using L-arginine supplementation and NO donation to modify the L-arginine-NO 
pathway has been studied as a novel therapy to slow the rate of progressive renal 
disease. However, as outlined before, L-arginine or NO donation have the potential 
both to protect and to harm the kidney [16, 55, 69]. It has been asked if the beneficial 
effect of L-arginine is indeed mediated through NO, and how we can mimic its 
therapeutic potential. In the injury phase of anti-thy1 glomerulonephritis, due to the loss 
of the sGC enzyme, Bay 41-2272 cannot elevate the disrupted cGMP production, and 
then the detrimental action of the L-arginine-NO pathway is dominant. In contrast, 
markedly increased cGMP levels in the matrix expansion and progression phases 
through Bay 41-2272 administration resulted in an antifibrotic effect. These data expand 
our understanding of previous investigations of anti-thy1 glomerulonephritis using L-
arginine supplementation or NO donation. Given the L-arginine-NO-cGMP signaling 
cascade, the very similar beneficial effects on TGF-beta overexpression and inhibition 
of ECM accumulation achieved by the sGC stimulator indicate that L-arginine and NO 
donation mediate its antifibrotic actions via cGMP signaling. 
Furthermore, this study suggests that pharmacological enhancement of the NO-
cGMP pathway may be a reasonable strategy to overcome important limitations of L-
arginine supplementation or NO donation in treating progressive renal fibrosis, including 
the production of cytotoxic NO, the generation of endogenous L-arginine metabolites 
and unwanted pro-oxidant activity. Therefore, sGC stimulators can differentiate 
between the beneficial and detrimental actions of the L-arginine-NO pathway. The new 
class of sGC enhancers, such as Bay 41-2272, acts in a functionally very specific 
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manner on the L-arginine-NO-cGMP signaling to amplify the cGMP signal exactly at 
that sub-cellular place where further cGMP effector pathways are already lined up. 
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5 Summary 
The expression and activity of the NO-cGMP signal transduction were analyzed 
during the injury, matrix expansion and progression phases in the rat model of anti-
thy1-induced renal disease. In order to further characterize the role of NO-cGMP 
signaling, the activity of sGC and subsequent cGMP production were specifically 
enhanced with the novel orally applicable compound Bay 41-2272.  
Acute anti-thy1 glomerulonephritis was induced by anti-thy1 antibody injection into 
rats with two kidneys, while anti-thy1-induced chronic glomerulosclerosis was produced 
by injecting anti-thy1 antibody into uni-nephrectomized rats. In protocol 1 (injury phase, 
day 1), Bay 41-2272 treatment was begun 6 days before and continued until one day 
after antibody injection. In protocol 2 (matrix expansion phase, day 7), Bay 41-2272 
treatment was started one day after antibody injection and was continued until day 7. In 
protocol 3 (progression phase, week 16), treatments with Bay 41-2272 or hydralazine 
as sole vasodilator control were started one week after disease induction and lasted 
until week 16. 
In the injury phase, glomerular expression and activity of the sGC were markedly 
down-regulated, while NO-cGMP signaling was highly up-regulated during the 
subsequent matrix expansion phase. During the progression phase, the glomerular and 
tubulointerstitial sGC pathways were discordantly altered, showing markedly up-
regulated sGC expression and activity in tubulointerstitial fibrosis and depressed NO-
cGMP signaling in persisting glomerulosclerosis. These data show that the sGC activity 
is highly regulated at the transcriptional level during the course of renal fibrosis, and 
correlates closely with the pathological changes from the injury over the matrix 
expansion toward the final progression phase. The results indicated that the sGC 
enzyme plays an active and independent role in NO signaling and that the 
pathophysiologic phenotype of “NO deficiency” results not only from reduced synthesis 
of NO, but also from the impaired subsequent production of its signaling molecule 
cGMP.  
The sGC stimulator Bay 41-2272 significantly enhanced renal NO-stimulated cGMP 
production and thereby limited TGF-beta overexpression and matrix protein 
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accumulation in the matrix expansion phase of acute anti-thy1 glomerulonephritis. In 
the injury phase, Bay 41-2272 failed to improve NO-cGMP signaling due to a complete 
loss of sGC expression and thus could not interfere with the anti-thy1 antibody-induced 
glomerular mesangial cell damage. In the progression phase, treatment with Bay 41-
2272 significantly slowed the progressive course of the anti-thy1-induced chronic 
glomerulosclerosis model towards glomerular sclerosis, tubulointerstitial fibrosis and 
impaired renal function. The sole vasodilator hydralazine did not affect NO-cGMP 
signaling and the progressive fibrosis and insufficiency, suggesting an at least partially 
blood pressure-independent mode in the renoprotective action of Bay 41-2272. Further 
analyses revealed that theses pressure-independent effects of Bay 41-2272 were 
related to a direct reduction in the expression of the key fibrosis mediator TGF-beta1 
and to a decrease in renal platelet deposition and macrophage infiltration. Taken 
together, these results indicate that pharmacological stimulation of sGC activity 
represents a novel, blood pressure-independent approach to limiting renal matrix 
accumulation and to slowing the progressive loss of function in chronic renal disease. 
The use of L-arginine supplementation to increase renal NO synthesis has 
previously been shown to have both beneficial and detrimental consequences in 
experimental kidney disease. The findings of this study indicate that the beneficial L-
arginine actions are likely to be mediated via subsequent NO-cGMP signaling and that 
specific stimulation of sGC activity is a feasible mode of separating the positive and 
negative effects of L-arginine administration in renal disease. Beyond the models of 
anti-thy1-induced renal disease, the results presented here are likely to open new 
perspectives in the understanding and treatment of renal disease in general. Ongoing 
TGF-beta overexpression and progressive renal matrix accumulation are hallmarks of 
most, if not all, chronic experimental and human kidney disorders. Thus, further studies 
are warranted in order to analyze whether the sGC enzyme also plays an independent 
role in other chronic renal diseases, such as experimental and human hypertensive and 
diabetic nephropathy, and whether enhancement of NO-cGMP signaling will limit their 
course towards progressive renal fibrosis and insufficiency. 
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6 Zusammenfassung 
Im Rattenmodell der Anti-Thy1-induzierten Nierenfibrose wurde die Expression und 
Aktivität der NO-cGMP-Signaltransduktionskaskade während der Schädigungs-, 
Matrixexpansions- und Progressionsphase untersucht. Zur weiteren Charakterisierung 
der Rolle der NO-cGMP-Signaltransduktion wurden die Aktivität der löslichen 
Guanylatzyklase und die nachfolgende cGMP-Produktion spezifisch mit dem oral 
anwendbaren, neuen Wirkstoff Bay 41-2272 stimuliert. 
Die akute Anti-Thy1-Glomerulonephritis wurde durch eine Anti-Thy1-
Antikörperinjektion in Wistar-Ratten mit zwei Nieren induziert, während die chronische 
Anti-Thy1-Glomerulosklerose durch eine Anti-Thy1-Antikörperinjektion bei uni-
nephrektomierten Ratten eingeleitet wurde. Im Protokoll 1 (Schädigungsphase, Tag 1) 
begann die Behandlung mit Bay 41-2272 sechs Tage vor und endet einen Tag nach der 
Antiköperinjektion. Im Protokoll 2 (Matrixexpansionsphase, Tag 7) wurde die 
Behandlung mit Bay 41-2272 einen Tag nach der Antikörperinjektion begonnen und bis 
zum siebten Tag fortgeführt. Im Protokoll 3 (Progressionsphase, 16 Wochen) wurde die 
Behandlung mit Bay 41-2272 eine Woche nach der Erkrankungsinduktion begonnen 
und in 15 Wochen beendet. In diesem Protokoll wurde als interne Kontrolle eine 
Gruppe von nierenkranken Tieren mit dem reinen Vasodilator Hydralazin behandelt. 
In der Schädigungsphase war die glomeruläre Expression und Aktivität der löslichen 
Guanylatzyklase hoch signifikant vermindert, während die NO-cGMP-
Signaltransduktion in der nachfolgenden Matrixexpansionsphase deutlich hochreguliert 
gefunden wurde. Während der Progressionsphase veränderten sich die glomeruläre 
und tubulointerstitielle sGC-Signalvermittlung diskontinuierlich und zeigte eine merklich 
hochregulierte sGC-Expression und -Aktivität in Gegenwart von tubulointerstitieller 
Fibrose und eine verminderte NO-cGMP-Signalaktivität bei persistierender 
Glomerulosklerose. Diese Befunde dokumentieren, dass die Aktivität der löslichen 
Guanylatzyklase im Verlauf von akuter und chronischer Nierenfibrose erheblich und 
eigenständig auf der transkriptionellen Ebene reguliert wird und dass die 
transkriptionell-vermittelten Veränderungen der sGC-Aktivität eng mit den 
pathologischen Veränderungen der Schädigungs-, Matrixexpansions- und 
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Progressionsphase korrelieren. Die Ergebnisse weisen darauf hin, dass das sGC-
Enzym eine aktive und unabhängige Rolle im NO-Signalweg spielt und dass der 
pathophysiologische Phänotyp „NO-Mangel“ nicht nur als Folge verminderter NO-
Synthese, sondern auch aus unzureichender Produktion seines Signalmoleküls cGMP 
resultieren kann.  
Der sGC-Stimulator Bay 41-2272 verstärkte signifikant die renale NO-stimulierte 
cGMP-Produktion. In der Matrixexpansionsphase der akuten Anti-Thy1-
Glomerulonephritis ging die gesteigerte NO-cGMP-Produktion mit signifikant 
verminderter glomerulärer TGF-beta-Überexpression und Matrixakkumulation einher. 
Infolge des fast vollständigen Verlustes der sGC-Expression in der Schädigungsphase 
war Bay 41-2272 nicht in der Lage die NO-cGMP-Signaltransduktion zu verbessern, so 
dass die Anti-Thy1-Antikörper-induzierte Mesangialzellschädigung auch nicht 
beeinflusst wurde. In der Progressionsphase des chronischen Anti-Thy1-
Nierenfibrosemodells verlangsamte die Behandlung mit Bay 41-2272 den eigenständig 
fortschreitenden Verlauf der Erkrankung zur Glomerulosklerose, tubulointerstitiellen 
Fibrose und eingeschränkten Nierenfunktion. Im Gegensatz zu Bay 41-2272 hatte der 
Vasodilator Hydralazin keinen Einfluss auf die NO-cGMP-Signaltransduktion und die 
Progression von renaler Fibrose und Insuffizienz. Dieses spricht dafür, dass die 
nephroprotektiven Effekte von Bay 41-2272 zumindest teilweise über Blutdruck-
unabhängige Mechanismen vermittelt werden. In weitere Analysen konnte gezeigt 
werden, dass diese blutdruckunabhängigen Wirkungen von Bay 41-2272 zum Teil über 
eine direkte Reduktion der Expression des zentralen Fibrosemediators TGF-beta1 und 
eine Verminderung der renalen Thrombozytendeposition und Makrophageninfiltration 
vermittelt werden. Zusammengefasst zeigen die Ergebnisse in der Matrixexpansions- 
und Progressionsphase, dass die pharmakologische Stimulation der sGC-Aktivität 
einen neuen blutdruckunabhängigen Ansatz darstellt, um die pathologische renale 
Matrixakkumulation zu vermindern und den progressiven Funktionsverlust von 
chronischen Nierenerkrankung zu verlangsamen. 
Über die Modelle Anti-Thy1-induzierten Nierenerkrankungen hinaus, zeigen die 
Ergebnisse dieser Arbeit neue Perspektive im Verständnis und der Behandlung von 
Nierenerkrankung im Allgemeinen auf. Es ist zuvor gezeigt worden, dass die Gabe von 
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L-Arginin zur Steigerung der renalen NO-Synthese sowohl mit günstigen als auch mit 
ungünstigen Effekten auf experimentelle Nierenerkrankung einhergehen kann. Die 
Resultate dieser Arbeit weisen darauf hin, dass die protektiven L-Arginineffekte 
wahrscheinlich über eine gesteigerte NO-cGMP-Signaltransduktion vermittelt werden 
und dass mittels der spezifische Stimulation der sGC-Aktivität ein praktisch 
anwendbarer Modus gefunden ist, um die günstigen und ungünstigen Wirkungen des L-
Argininstoffwechsels bei Nierenerkrankung zu trennen. Da die meisten chronischen 
experimentellen und humanen Nierenerkrankungen gleichermaßen durch fortlaufende 
TGF-beta-Überproduktion und progressive Nierenmatrixakkumulation gekennzeichnet 
sind, sollten zukünftige Studien analysieren, ob auch in anderen chronischen 
Nierenerkrankungen, wie z. B. der hypertensiven und diabetischen Nephropathie, die 
lösliche Guanylatzyklase eine unabhängige Rolle spielt und ob sich auch hier über eine 
Verbesserung der NO-cGMP-Signaltransduktion das Fortschreiten zur progressiven 
Nierenfibrose und Insuffizienz verzögert werden kann. 
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Abbreviations 
°C Degrees Celsius 
aGN Acute glomerulonephritis 
APAAP Alkaline Phosphatase and Anti-Alkaline Phosphatase 
ATP Adenosine triphosphate 
cDNA Complementary DNA 
CO2 Carbon dioxide 
cGMP cyclic guanosine monophosphate 
cGS Chronic glomerulosclerosis 
dATP Deoxyadenosine 5´-triphosphate 
dCTP Deoxycytidine 5´-triphosphate 
dGTP Deoxyguanosine 5´-triphosphate 
dTTP Deoxythymidine 5´-triphosphate 
DEA/NO Diethylamine-NONOate 
DEPC Diethyl Pyrocarbonate 
DNA Deoxyribonucleic acid 
DMEM Dulbecco’s Modified Eagle’s Medium 
dsDNA Double-stranded DNA 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
ELISA  Enzyme-Linked Immunosorbent Assay 
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GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GTP  Guanosine 5`-triphosphate 
HRP Horseradish peroxidase 
H2SO4 Sulphuric acid 
HCl Hydrochloric acid 
IBMX 3-Isobutyl-1-methylxanthine 
Ig Immunoglobulin 
LPS Lipopolysaccharide 
Min Minutes 
mRNA Messenger ribonucleic acid 
NADPH Nicotinamide Adenine Dinucleotide Phosphate Reduced 
NO Nitric oxide 
NOS NO synthase 
eNOS Endothelial NOS 
iNOS Inducible NOS 
nNOS Neuronal NOS 
OPD O-Phenylenediamine dihydrochloride 
PAI-1 Plasminogen-activator-inhibitor-type 1 
PAS Periodic acid Schiff 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
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PDE Phosphodiesterase 
PKG cGMP-dependent protein kinase 
rpm Revolutions per minute 
RPMI Roswell Park Memorial Institute medium 
sec Seconds 
sGC Soluble guanylate cyclase 
TBS Tris-buffered saline 
TGF-beta Transforming growth factor-beta 
TNF-alpha Tumor necrosis factor-alpha 
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